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Summary 
Breast cancer is one of the leading causes of death for women worldwide. Patients whose 
tumors express Estrogen Receptor α (ERα) account for ~70% of cases, and can be treated with 
targeted endocrine therapy. Endocrine therapy abrogates estrogen (E2) mediated tumor 
growth either by blocking the ER itself (tamoxifen, fulvestrant) or by inhibiting the enzyme 
responsible for E2 production (aromatase inhibitors). However, around 40% of the patients 
eventually relapse due to resistance development. While several advancements have been 
made and second-line treatments are available for relapsing patients, resistance remains an 
urgent clinical problem that needs to be addressed. To investigate the mechanisms underlying 
development of resistance to endocrine therapies, I utilized various strategies to tackle two 
different aspects. To identify novel drivers of resistance, I developed new resistant cell lines and 
investigated the early phases of the resistance process with a combination of high throughput 
techniques. The analysis revealed ATF3 as a putative regulator of the response to therapy and 
of the rewiring of cells' central processes. The role of ATF3 was validated in vitro modulating its 
expression through knockout, knockdown and overexpression. ATF3 was identified to be 
essential in controlling proliferation, cell cycle and apoptosis rate of the cells under treatment 
through the regulation of MAPK/AKT signaling pathways. Its role was confirmed in vivo in a 
xenograft mouse model and the high expression levels were verified in patient datasets, adding 
clinical relevance to the findings. The second aspect I investigated was the relevance of clonality 
in endocrine therapy resistance. To do this, I used a cellular barcoding approach to track single 
cells during resistance development against tamoxifen and E2 deprivation in vitro. The analysis 
of the barcodes complexity in resistant clones revealed cell line-specific and treatment-specific 
mechanisms of resistance development. The distinct barcodes composition also reflected 
different signaling pathways activities that indicate specific paths to resistance for the 
independent replicates. Overall this study elucidates key features of endocrine resistance both 
through the identification of ATF3 as a novel mediator of endocrine resistance and through the 
dissection of the mechanisms underlying the selection/adaptation of independent replicates to 
the endocrine treatments. 
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Zusammenfassung 
Brustkrebs ist eine der führenden Todesursachen bei Frauen weltweit. Patientinnen deren 
Tumore den Östrogenrezeptor α (ERα) exprimieren machen ~70 % aller Fälle aus und können 
mittels gezielter endokriner Therapie behandelt werden. Die endokrine Therapie unterbindet 
das Östrogen- (E2) abhängige Tumorwachstum entweder durch Blockierung des ER (Tamoxifen, 
Fulvestrant) oder durch die Inhibierung des Enzyms, welches für die E2-Produktion 
verantwortlich ist (Aromatase-Inhibitoren). Nichtsdestotrotz rezidivieren ungefähr 40 % der 
Patientinnen letztendlich aufgrund einer Resistenzentwicklung. Obwohl einige Fortschritte 
gemacht wurden und Zweitlinientherapien für rezidivierende Patientinnen verfügbar sind, 
bleibt die Resistenz ein dringliches klinisches Problem, das adressiert werden muss. Um 
diejenigen Mechanismen, die der Resistenzentwicklung gegenüber endokrinen Behandlungen 
zugrunde liegen, zu untersuchen, verwendete ich verschiedene Strategien um zwei 
unterschiedliche Aspekte anzugehen. Um neuartige Treiber der Resistenz zu identifizieren, 
entwickelte ich neue resistente Zelllinien und untersuchte die frühen Phasen des 
Resistenzprozesses durch eine Kombination von Hochdurchsatztechniken. Die Analyse enthüllte 
ATF3 als vermutlichen Regulator der Therapieantwort und der Neuvernetzung der zentralen 
zellulären Prozesse. Die Rolle von ATF3 wurde in vitro durch Modulation der Genexpression 
mittels Knockout, Knockdown und Überexpression validiert. ATF3 wurde als essenziell für die 
Kontrolle von Proliferation, der Zellzyklus- und Apoptose-Rate der Zellen unter Behandlung 
durch Regulation der MAPK/AKT Signalwege identifiziert. Seine Rolle wurde in vivo in einem 
Xenograft-Mausmodell bestätigt und die hohen Expressionslevel in Patientinnendatensätzen 
verifiziert, was den Ergebnissen klinische Relevanz hinzufügte. Der zweite Aspekt, den ich 
untersuchte, war die Relevanz von Klonalität in der endokrinen Therapieresistenz. Dazu 
verwendete ich einen zellulären Barcoding-Ansatz um einzelne Zellen während der 
Resistenzentwicklung gegen Tamoxifen und E2-Entzug in vitro zu verfolgen. Die Analyse der 
Barcode-Komplexität in resistenten Klonen enthüllte Zelllinien-spezifische und Behandlungs-
spezifische Mechanismen der Resistenzentwicklung. Die verschiedenen Barcode-
Zusammensetzungen spiegelten auch unterschiedliche Signalwegaktivitäten wider, die auf 
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spezifische Wege zur Resistenz in den unabhängigen Replikaten hinweisen. Insgesamt klärt 
diese Studie Schlüsselmerkmale der endokrinen Resistenz sowohl durch die Identifikation von 
ATF3 als neuartigen Treiber der endokrinen Resistenz als auch durch die Zergliederung von 
Mechanismen, die der Selektion/Adaption von unabhängigen Replikaten gegenüber endokrinen 
Behandlungen unterliegen, auf. 
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1. Introduction 
1.1. Breast Cancer  
Cancer is one of the main public health concerns worldwide, estimated to have 18.1 million of 
new cases and 9.6 million cancer deaths, being the second leading cause of death globally after 
cardiovascular diseases (“WHO | Cancer” 2019; Bray et al. 2018). Breast cancer is the most 
diagnosed type of cancers among women, accounting for 25-30% of all new cancer diagnosis, 
and the second-leading cause of death after lung cancer (Siegel, Miller, and Jemal 2019).  
Since breast cancer is a highly heterogeneous disease, a generalized therapeutic approach 
cannot be successfully applied in the clinic. For this reason, many studies have focused on this 
issue trying to stratify patients to find therapeutic subtypes that would benefit from specific 
treatments. 
 
1.1.1 Histopathological classification 
Breast cancer can be histologically divided in ductal carcinoma in situ (DCIS) or invasive 
carcinoma (IDC) with the latter accounting for the majority of the cases (Vuong et al. 2014). IDC 
is subdivided in more than 20 subtypes, with the not defined subtype, the invasive carcinoma 
not otherwise specified (IDC NOS) being the most abundant, accounting for 50-80% of all breast 
cancers (Weigelt et al. 2008). The other subtypes are characterized by special features and 
include the invasive lobular, tubular, mucinous, metaplastic, neuroendocrine, medullary and 
apocrine carcinomas (Vuong et al. 2014). The histological grading of the tumors is done based 
on specific guidelines, which consider the proportion of tubule formation, the degree of nuclear 
pleomorphism and the mitotic count (Elston and Ellis 1991).  
The scoring grades of breast tumors can range from 1 to 3, with 1 being the most 
differentiated. High-grade cancers tend to recur more and metastasize early, while low-grade 
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tumors have a better clinical outcome. Pathologically, breast tumors are staged based on the 
TNM guidelines that consider the tumor size(T), the status of the lymphnodes (N) and the 
spread to distant sites (M) (Giuliano, Edge, and Hortobagyi 2018). 
 
1.1.2 Molecular subtypes 
In order to stratify patients based on the clinical outcome and therapeutic strategies, breast 
cancers have been subdivided based on the expression of specific genes. Specifically, breast 
cancer can be classified using intrinsic or clinical subtypes. The intrinsic subtyping is based on 
gene expression profiling, with classifiers that divide the breast cancers in Luminal A (LA), 
Luminal B (LB), Her2-enrichded (HER2+), basal-like (Basal) and normal-like (Normal) (Table 1) 
(Perou et al. 2000). These classifiers are using an intrinsic list of genes to subdivide the tumors 
in these five classes (Sørlie et al. 2001; Hu et al. 2006; Parker et al. 2009). However, in the last 
years, the normal like subtype is less used as highly similar to the LA (Raj-Kumar et al. 2019). 
 The clinical sub-typing is instead based on immunohistochemistry (IHC) for estrogen receptor 
(ER), progesterone receptor (PR) HER2 receptor (HER2) and Ki-67. These markers are regularly 
used in the clinic and they are the only accepted stratification method for treatment decision 
making (Inwald et al. 2015). Based on the IHC markers the tumors are divided in LA 
(ER+/HER2−/Ki67−), LB (ER+/HER2−/Ki67+ or ER+/HER2+), HER2 (ER−/PR−/HER2+), Triple 
negative (TN; ER−/PR−/HER2−) (Goldhirsch et al. 2013).  
Since the two classification methods do not completely overlap, new assays and gene sets are 
proposed regularly to try to improve the consistency of subtypes definition in breast cancer 
(Milioli et al. 2016; Raj-Kumar et al. 2019). As a notable example, a recent clustering analysis 
based on genomic and transcriptomic analysis of 2000 breast cancer proposed a 10 subgroups 
classification to further stratifies the intrinsic subtypes, with well characterized genomic 
features and distinct clinical outcome (Table 1) (Curtis et al. 2012). 
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Table 1: Molecular subtypes of breast cancer (Modified from Vuong et al. 2014) 
 
 
1.1.3 Luminal 
Luminal tumors are the most abundant subtype, accounting for around 70% of all breast 
cancers. They are characterized by the expression of hormone receptors for estrogen alpha 
(ERα) and/or progesterone (PR). Their expression profiles are similar to the luminal epithelial 
cells of the normal breast, with high expression of ER related genes and lower expression of 
proliferation related genes. Indeed, tumors belonging to the luminal subtype are generally 
having lower grade and slower growth compared to other subtypes. Luminal tumors can be 
further subdivided into luminal A and luminal B that account for 50% and 20% of all breast 
cancer respectively. Histologically, luminal A tumors are ER+ and/or PR+, HER2- and express low 
levels of Ki67, while luminal B can either be ER+ and/or PR+ and HER2+ with low Ki67, or ER+ 
and/or PR+ and HER2- with high Ki67 (Dai et al. 2015).  
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Luminal A tumors are characterized by a low-grade, a high differentiation and slow 
proliferation. In comparison, luminal B tumors are showing higher grade and a poor 
differentiation with a high proliferation rate as reflected by the high levels of ki67. Luminal A 
cancers key molecular features include the high expression of ER-related genes as ESR1, FOXA1, 
XBP1 and high mutations rate in PIK3CA (45%), MAP3K1 (13%) and GATA3 (14%) (Cancer 
Genome Atlas Network 2012). Luminal B subtype has high expression of proliferative genes 
MYC and FOXM1, higher genomic instability with mutation in PIK3CA (29%) and TP53 (29%) and 
amplification in CCND1 and MDM2 (Cancer Genome Atlas Network 2012).  
Given the high expression of ER and the dependency on estrogen for the growth, luminal 
patients are commonly treated with endocrine therapy and the availability of targeted 
therapies for luminal cancers make them the ones with the most favorable prognosis. Luminal A 
tumors are highly responsive to this treatment with low response rate to traditional 
chemotherapy. On the other hand, luminal B tumors have a minor benefit from endocrine 
therapy treatment alone and a better response to chemotherapy, particularly in neoadjuvant 
setting (Ades et al. 2014) 
 
1.1.4 HER2-enriched 
HER2-enriched (HER2+) subtype is characterized by the amplification and/or overexpression of 
the HER2, the lack of expression of hormone receptors ER and PR and high levels of ki67. 
Clinically they are identified by IHC or fluorescent in situ hybridization (FISH) (Dai et al. 2015). 
Other molecular features include mutations in TP53 (72%) and PIK3CA (39%) and high 
molecular instability. HER2+ breast cancer includes around 15% of all breast cancers and is 
associated with a more aggressive clinical course compared to the luminal subtype (Cancer 
Genome Atlas Network 2012). HER2 is a member of the epidermal growth factor receptors and 
following dimerization can activate a variety of signaling pathway leading to uncontrolled cell 
growth. The use of monoclonal antibodies directed against HER2, namely pertuzumab and 
trastuzumab, are highly effective in the treatment of this subtype (Swain et al. 2015). 
 
23 
 
Particularly their use in combination with chemotherapy is standard practice for patients with 
this disease. One of the major clinical problems related to the use of these antibodies is the 
arise of resistance and to tackle this problem this antibodies have been conjugated with 
cytotoxic components as emtansine (DM-1) to increase the response rate in second line 
therapy (Bartsch and Bergen 2018).  
 
1.1.5 Triple negative / Basal 
Triple negative breast cancer (TNBC) is identified by the lack of expression of ER, PR and Her2 
and a high level of ki67 and accounts for around 15% of all breast cancers. This histologically-
define subtype mostly overlap the intrinsic classification of basal-like tumors (Vuong et al. 
2014). The triple negative tumors are highly undifferentiated and aggressive having the worst 
prognosis among the different breast cancer subtypes. Molecular features include germline 
and/or somatic BRCA1 and BRCA2 mutations, the overexpression of cytokeratin CK 5/6 and 
CK14 typical of the basal compartment of the normal breast, as well as high mutation in TP53 
and genomic instability (Cancer Genome Atlas Network 2012).  
They usually present as grade 3 tumors with high heterogeneity and this has led to particular 
effort to try to substratify this group of patients. One classification divided TNBC in this subtype 
into 6 sub-subtypes, 2 basal-like (BL1 and BL2), 1 immunomodulatory (IM), 1 mesenchymal (M), 
1 mesenchymal stem-like (MSL) and 1 luminal androgen receptor (LAR) subtype(Lehmann et al. 
2011). This classification was later refined to include only 4 sub-subtypes, namely BL1, BL2, M 
and LAR (Lehmann, Jovanovi, et al., 2016). Independently of the classification, TNBC remain 
highly aggressive mainly due to the lack of targeted therapies that are instead available for the 
Luminal and Her2-enriched subtypes. Clinically they are treated mostly with anthracycline, 
platinum or taxane-based chemotherapy, but the overall survival remains the lowest (Foulkes, 
Smith, and Reis-Filho 2010). 
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1.1.6 Endocrine therapy 
The standard treatment for breast cancer patients involves surgery and/or radiotherapy. 
Depending on the subtype of breast cancer, patients may undergo additional treatments which 
include chemotherapy or targeted therapy, like endocrine therapy or monoclonal antibodies. 
These treatments can be administered in neo-adjuvant setting, to shrink the tumor before 
surgery, or adjuvant setting, as a long-term maintenance treatment and to hit potential 
metastasis. 
Endocrine therapy is the most used treatment for hormone receptor positive breast cancers 
(Liedtke and Kolberg 2016). It consists in different drugs that act by abrogating the estrogen 
induced ER activation. Antiestrogens can be divided in Selective ER modulators (SERMs), like 
tamoxifen, that act by competitively inhibiting the estrogen binding to ERα, and selective ER 
downregulators (SERDs), like fulvestrant, which bind the ER and lead to its degradation. 
Another class of agents used for endocrine therapy are the aromatase inhibitors (AIs), like 
letrozole, that block the enzymes involved in the synthesis of estrogen (Traboulsi et al. 2017). 
 
Figure 1: Mechanism of action of endocrine therapy (Chan, Petrossian, and Chen 2016) 
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1.1.7 SERMs - Tamoxifen 
SERMs are the first antiestrogen drugs used for the treatment of breast cancer. They are a class 
of nonsteroidal compounds that function as ligands for ER. Tamoxifen was the first to be 
approved by FDA in 1970 and it has been used since as adjuvant treatment for ER+ primary 
breast cancer of all stages, proved to effectively decrease the mortality rate (Smith 2014). Even 
though many tamoxifen-analogues of have been developed and tested to try to reduce side 
effects and increase efficacy (tamofitoremifene, droloxifene, idoxifene, raloxifene, arzoxifene, 
lasofoxifene, basedoxifene), tamoxifen is still the most effective and most used in the clinic 
(Arnott et al. 2014). It is routinely delivered as a 5-year long treatment after surgery and recent 
trials suggest that a even longer treatment period of 10 years might have even higher efficacy 
in reducing relapse and mortality rates (Davies et al. 2013).  
Even though tamoxifen has an antagonist activity in breast cancer cells, it has a estrogenic-like 
effect in the bones and uterus, thus being associate with an increased risk of endometrial 
cancer (Da Vies, Syne and Nicholson, 1979). Tamoxifen treatment is mostly used for pre-
menopausal patients, where the ovaries activity prevents the use of AIs. This is mainly because 
the ovaries are the main source of estrogen for pre-menopausal women and exposure to AIs 
would induce an increase in gonadotrophin secretion, that in turn would increase the 
production of more estrogen in the ovaries, having the opposite effect (Scharl and Salterberg 
2016). 
 
1.1.8 SERDs - Fulvestrant 
To minimize agonist activity of SERMs and tackle resistance, a new class of antiestrogens was 
developed. This group of drugs includes steroidal compounds of which the most used is 
fulvestrant. Fulvestrant is a "pure" ER antagonist, with a binding affinity to the receptor 100 
times higher than tamoxifen. Additionally the binding induce the rapid degradation of the 
receptor, thus decreasing even further the ability of ER to activate gene transcription (Boér 
2017). Fulvestrant is routinely used as a second line therapy for postmenopausal women after 
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resistance to first line endocrine therapy (tamoxifen or AIs). Recent trials however proved the 
efficacy of fulvestrant also as first line, alone or in combination with AIs (Robertson et al. 2016). 
More studies are needed to prove if fulvestrant is an effective and tolerable alternative to 
standard first line endocrine therapy and which patients might benefit mostly from its direct 
administration. 
 
1.1.9 Aromatase inhibitors 
Aromatase inhibitors (AIs) act by inhibiting aromatase, an enzyme that belongs to the 
cytochrome p450 superfamily and catalyze the aromatization of androstenedione to estrone 
and testosterone to estradiol (Mantas et al. 2016). There are three generations of AIs based on 
the year of development and they are further classified in type 1 and type 2. Type 1 inhibitors 
are steroidal analogues of androstenedione that irreversibly bind to aromatase while type 2 
inhibitors are non-steroidal and bind reversibly to the heme group of the aromatase. The third 
generation AIs have been developed in 1990 and are the only ones regularly used in clinic. They 
include both type 1 (anatrozole and letrozole) and type 2 inhibitors (examestane) (Wood, 
Smith, and Dowsett 2003).  
As stated before AIs are can only be used to treat postmenopausal women and they are the 
treatment of choice for these patients both in first and second line therapy. However, given the 
efficacy, recent studies are proposing the implementation of ovarian suppression of ablation 
and AIs administration also for premenopausal women (Rugo et al. 2016). Additionally several 
trials have proven the enhanced efficacy of AIs when used in combination with other drugs as 
CDK4/6 inhibitors or mTOR inhibitors and these regiment are now being considered for clinical 
application in second and third line setting (Flaum and Gradishar 2018). 
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1.1.10 Resistance to endocrine therapy 
Despite the clear benefit of endocrine therapy for patients with ER+ breast cancer, resistance to 
the treatment is a critical clinical issue that involves a large number of patients. Several studies 
have shown that recurrence to endocrine therapies occurs in approximately 10-15% of patients 
within 5 year (Dowsett et al. 2010). This numbers rises to 30% after 15 years from the therapy 
administration, and eventually up to 40-50% of the patients will relapse (Cynthia X. Ma 2009; 
EBCTCG 2005). Resistance can occur due to several factors and this adds complexity to the 
difficult task to identify drivers of this phenomena to target in the clinic (Figure 2) (Dixon 2014; 
Murphy and Dickler 2016).  
 
Figure 2: Mechanisms of endocrine therapy resistance (Modified from Dixon JM, 2014) 
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1.1.10.1 Hormone receptors status and modifications 
Estrogen Receptor (ER) is the target molecule of endocrine therapy and many alterations in its 
expression or activity have been proved to be involved in resistance development. These can be 
summarized in: 
 ESR1 mutations: activating mutations on ESR1 gene are mostly found in the ligand 
binding domain and are responsible for its activation even in absence of a ligand. They 
are occurring in about 11-39% of relapsing patients and the mutations are generally not 
present in the primary tumors, identifying this as a mechanism of acquired resistance 
(Reinert et al. 2017). Highly reported alterations on ESR1 are Y537S and D538G that are 
having an occurrence rate of 13% and 21% respectively and have been associated with 
shorter overall survival (Chandarlapaty et al. 2016; Merenbakh-Lamin et al. 2013). 
 Tumor heterogeneity and ER expression: the IHC classification of a tumor considers it 
ER+ if more than 1% of the cells in the tumor are stained. This makes some tumors (or 
parts of it) not responsive to this specific treatment that may not be the appropriate 
therapy choice for this patients in the first place (Harbeck and Rody 2012). 
 ER post-translational modifications: ER can be modified by a number of post-
translational modifications (phosphorylation, acetylation, sumoylation) that can 
influence the activity, stability and binding of ER to target genes even in absence of a 
ligand (Heo 2019). 
 Differential ER binding: ER can selectively bind to specific Estrogen Responsive Elements 
(EREs) in open chromatin regions, helped and directed in this by FOXA1 and other 
factors. Reports have shown that the activities of these co-factors can adjuvate ER 
binding in tamoxifen-resistant tumors (Ross-Innes et al. 2012) 
 ERα-independent signaling: ER+ tumor treated with endocrine therapy can lose their ER 
expression (15-20%) and rely for their proliferation on ERα independent mechanisms. 
These involve, among others, the activity of additional estrogen-regulated receptors, 
like estrogen receptor β (ERβ) and estrogen-related receptor γ (ERRγ) (Heckler et al. 
2014; Speirs et al. 1999). 
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ER is not the only receptor that is screened with IHC for the classification of patients. PR, an 
hormone receptor for progesterone, is indeed expressed in many ER+ tumors, but some 
patients are ER+/PR- and this has been shown to affect prognosis and response to therapy (Díaz 
Flaqué et al. 2013). 
 
1.1.10.2 Crosstalk with other growth signaling pathways 
Receptor tyrosine kinases (RTKs) are some of the main mediators of growth signaling in the cells 
and many of these growth factor receptors, like EGFR, HER2, HER3, FGFR1 and IGFR1, are 
associated with endocrine resistance (Murphy and Dickler 2016). Their activation and further 
signal propagation is estrogen independent as it is induced by receptor specific ligands as EGF, 
FGF or IGF. These receptors converge downstream in the PI3K/AKT/mTOR and ERK/MEK 
pathways, thus promoting estrogen-independent proliferation. However they can also 
phosphorylate and activate the ERα itself, thus overcoming the efficacy of endocrine therapies 
(Schiff et al. 2004).  
Overexpression of growth factor receptor is not the only mechanism by which these pathways 
can be activated. As mentioned before, PIK3CA is the most common mutation in breast cancer 
(40%) and in general mutation in the proteins involved in PI3K pathway are found in 
approximately 70% of breast cancer (Fu, Osborne, and Schiff 2013). Activating mutations in 
positive regulators of the pathway (PIK3CA, PIK3CB, AKT1, AKT2) or inhibiting mutation in 
negative regulators, like PTEN, could then promote both ER-dependent and ER-independent 
transcriptional activation and proliferation (Miller, Balko, and Arteaga 2011). Another pathway 
involved in proliferation and survival is the NFκB pathway and its crosstalk with the ER receptor 
has been deeply investigated in literature (Pradhan et al. 2010; Nettles et al. 2008). Alteration 
of this pathway have been reported in in vitro models of resistance and further studies are 
needed to clarify its role in this phenomena (Yde et al. 2012). 
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1.1.10.3 Cell-cycle dysregulation 
The deregulation of key cell cycle checkpoints and survival proteins are other contributors to 
the loss of response to endocrine therapy. CDK4/6 and CCND1 regulate the transition from G1 
to S phase via phosphorylation of RB1 and are important in highly proliferative cancer cells 
(Weinberg 1995). Several studies showed the aberrant expression of cell-cycle related 
molecules like cyclin-D1, c-MYC, RB1 and p21 in resistant tumors (Dixon 2014). The cyclin-D1 
dependent escape from senescence is one of the most common resistance associated events 
and can be caused by amplifications or mutations of CDK4, CDK6, cyclin-D1 or other related 
proteins (p16, p21) (Cancer Genome Atlas Network 2012). This has been shown to play an 
active role particularly in ER positive breast cancer as CCND1 is a direct target gene of ER and 
novel CDK4/CDK6 inhibitor are tested in the clinics with promising results (Pernas et al. 2018). 
 
1.1.10.4 Epigenetic regulation 
While many studies proved that genetics might have a role in therapy resistance, recent 
publications reported that epigenetic might have a major role in the acquisition of resistance to 
endocrine therapies. This role is exploited both at the DNA methylation level, with activation of 
oncogenes and silencing of tumor suppressor genes, and at the histone modification level, with 
changes in chromatin accessibility. DNA methylation exerts its role in resistance both by 
targeting the ER itself, by inducing promoter methylation, and genome wide, by changing the 
methylation levels of EREs (Stone et al. 2015; Martínez-Galán et al. 2014). At the same time, 
histone modifications and genome-wide rearrangement of chromatin have been identified as a 
common phenomenon in endocrine resistance (Patten et al. 2018; Abdel-Hafiz 2017).  
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1.1.10.5 Other resistance mechanisms 
Several other resistance mechanisms have been described in literature. Additional pathway 
have been reported to play a role in resistance development, including Notch and Wnt (Nguyen 
et al. 2015; Riggins et al. 2007). Particularly, their involvement in the maintenance of a 
population of cancer stem cells (CSCs) is important in keeping a subset of cells insensitive to the 
drug, thus promoting resistance (Piva et al. 2014; Lombardo et al. 2014). Other cellular 
processes, like metabolism, autophagy and epithelial-to-mesenchymal transition (EMT) have 
been proven play a role in resistance to endocrine therapy, even though their role remains 
poorly understood and further studies are needed to shed light in their involvement in the 
resistance process (Nguyen et al. 2015; Samaddar et al. 2008; Hiscox et al. 2006). 
There are also treatment-specific aspects to take into account. An example related to tamoxifen 
involves the status of the enzyme involved in its conversion to the active metabolite 4-hydroxy-
tamoxifen is the cytochrome P450 2D6. Patients lacking for this enzyme have been reported to 
be insensitive to tamoxifen treatment and other therapeutic options should be considered 
(Hoskins, Carey, and McLeod 2009). At the same time, regarding aromatase inhibitors, studies 
have shown that even if they deplete the tissues from estrogen, low levels remains and cells 
can develop hypersensitivity to this residual hormone levels, thus still activating ER-related 
pathways (Sikora et al. 2012). 
Overall resistance to endocrine therapy is complex and mediated by numerous cellular 
processes and pathways. Understanding the reasons and the driving mechanisms behind 
resistance development is essential to develop new clinical strategies to tackle resistance. 
 
1.1.11 Treatment of endocrine resistant breast cancer 
After the failure of first line endocrine therapy, recurrent ER+ breast cancer can be treated with 
alternative strategies to target growth and survival pathways responsible for the relapse (Figure 
3). As mentioned before, one of the therapeutic options is to use SERDs like fulvestrant to block 
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and degrade the ER. Fulvestrant can be use both in monotherapy or in combination either with 
other endocrine therapies or with approved drugs for advanced breast cancer, as CDK4/6 
inhibitors, mTOR inhibitors and PI3K inhibitors (Sammons, Kornblum, and Blackwell 2019). 
While the administration of fulvestrant alone is already beneficial for patients, with increased 
progression free survival (PFS) up to 6 months, its administration in combinatorial therapies 
showed better results in recent clinical trials, therefore opening the possibilities for more 
effective second line treatments (Schmid et al. 2018; Cristofanilli et al. 2016; Di Leo et al. 2018). 
 
 
Figure 3: Treatment of ER+ breast cancer (Modified from Cardoso et al., 2018) 
 
CDK4/6 inhibitors are small molecules that interfere with the G1-S phase transition during cell 
cycle by blocking CDK4 and CDK6 phosphorylation of Rb. Three different inhibitors are currently 
used in clinic trials to treat luminal breast cancer: palbociclib, ribociclib and abemaciclib (Cortés 
et al. 2017). They have been tested both as first and second line therapies in combination with 
standard endocrine therapies showing a consistent increase PFS (Vidula and Rugo 2016).  
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Inhibitors for mTOR and PIK3 are also being used in clinical trials in combination with endocrine 
therapy, given the importance of this pathway in the resistance process (Steelman et al. 2016). 
Rapamycin was the first mTOR inhibitor discovered and new derivatives of this drug are now 
tested in the clinic, as tensirolimus, everolimus and deforolimus. Several clinical trial using 
these inhibitors in combination with different endocrine therapies are under way and results 
show improved PFS and overall survival (Rotundo et al. 2016). PI3K inhibitors act upstream of 
mTOR and they are currently tested in clinical trials in combination with fulvestrant for second 
line therapy (Alpelisib, Buparsilib, Pictisilib). Initial results show promising effects, with a 
particular high efficiency in patients harboring mutations in PI3KCA (AlFakeeh and Brezden-
Masley 2018). Additionally studies are on-going to test the efficacy of the combination of both 
CDK4/6 and mTOR or PI3K inhibitors as second line treatment with AIs or fulvestrant (D’Souza, 
Spicer, and Lu 2018). 
Other therapeutic strategies currently tested are the combination of standard endocrine 
therapy with HDAC inhibitors (vorinostat and entinostat) or immunotherapy (anti-PD-1 and 
anti-PD-L1 antibodies) but further studies are needed to prove their efficacy (D’Souza, Spicer, 
and Lu 2018). 
 
1.2. Tumor heterogeneity 
Cancer is a heterogeneous disease. Heterogeneity does not only refers to the differences 
between patients having the same tumor (inter-tumor heterogeneity) but also to variation 
inside the tumor itself (intra-tumor heterogeneity) (Stanta and Bonin 2018). Indeed, at a 
specific time, tumors include different cells in terms of genetics, epigenetics or transient gene 
expression and this closely affects cancer progression and resistance to therapy. To explain this 
heterogeneity two general models have been described in literature: 
 Clonal evolution: genetic and epigenetic changes occur in individual cells through time, 
giving them selective advantage. These clones can therefore out-grow others becoming 
the dominant population in the tumor (Nowell 1976). 
 
34 
 
 Cancer stem cell: the growth and progression of tumors is driven by a subset of stem 
cells called cancer stem cells (CSCs). This cells are responsible for the initiation and 
maintenance of the tumors suggesting a hierarchical organization of tumor evolution 
(Lapidot et al. 1994; Reya et al. 2001) 
Even if the two models propose different interpretations of tumor heterogeneity, they are not 
mutually exclusive and it has been proved that they can both contribute to tumor progression. 
Indeed genetic and epigenetic events can affect both CSCs and daughter cells, giving rise to sub-
clones with phenotypic advantages (Figure 4) (J. Wang, Ma, and Cooper 2013).  
 
Figure 4: Models of tumor heterogeneity (Modified from Wang, Ma and Cooper, 2013) 
 
This heterogeneity is reflected in the spatial localization of specific cell in a tumor. Recent 
techniques allowed the deep molecular characterization of spatial heterogeneity confirming the 
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unequal distribution of molecular alterations across primary tumors in different types of cancer 
(Dagogo-Jack and Shaw 2018). This proves the limitation of biopsies and bulk analysis for 
therapy decision as important alterations might be masked based on the approach used. An 
additional layer to add to the heterogeneity of a tumor is the temporal heterogeneity. This can 
be caused both by the natural accumulation of mutation over time or by external factor. 
Indeed, several studies proved that therapy administration can change the molecular profile of 
tumors (Murugaesu et al. 2015; TCGA 2008). 
 
1.2.1  Role of tumor heterogeneity in drug resistance 
The heterogeneity of cancer cells, which can have different grade of sensitivity to therapies, is 
one of the main drivers of resistance development. This can be proven by the fact that many 
patients, after an initial response to drugs like chemotherapeutic agents or targeted therapies, 
relapse and are resistant if treated with the same compound (Garraway and Jänne 2012). There 
are two main reasons that can explain this phenomenon: 
 Resistant clones: presence in the tumor population of resistant clones to the therapy 
applied. While an initial response to the therapy is seen as the majority of sensitive cells 
die, the growth of the pre-resistant clone give rise to a relapse resistant to the same 
treatment (Dagogo-Jack and Shaw 2018). In several studies has been shown that low-
frequency alteration in pre-treatment tumors are selected and identified as the reason 
of the development of the resistance (Shaw et al. 2016; Yu et al. 2014). Additionally, 
evidence from in vitro barcoding experiments showed expansion of pre-existing 
resistant population to targeted therapies (Bhang et al. 2015; Hinohara et al. 2018). 
 Adaptation of “persister” clones: some clones in the bulk population survive the initial 
drug treatment and acquire additional alterations that later on confer resistance to the 
therapy. It has been described that these “persister” cells enter a long quiescent phase 
with no proliferation, during which a fraction of the initial population can gain the ability 
to expand (Hata et al. 2016; Ramirez et al. 2016). Some studies identified this "persister" 
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state to be transient and stochastic and mainly driven by epigenetic regulation rather 
than genetic mutations (Sharma et al. 2010; Shaffer et al. 2017). 
Due to this complexity in the tumor population, the characterization of tumors cells in time is 
essential to understand the dynamics of clones and choose the appropriate therapeutic 
regimen. Nowadays, the common practice in clinic is to make treatment decision based 
exclusively on pre-treatment biopsies, therefore limiting the information on a snapshot of the 
tumor. However, as it has been shown that therapy itself can cause the selective pressure to 
induce specific clonal selection, longitudinal sampling is needed also during therapy 
administration and even more after relapse. Additionally, the identification of clonal alterations 
is essential to implement combinatorial treatment that can have adjuvant role to standard 
therapy (Dagogo-Jack and Shaw 2018).  
 
1.2.2 Clonal heterogeneity in breast cancer 
Breast cancers are not homogeneous population of cells and as such the single cells in the 
tumor have different characteristics and response to the drugs. A clear example in ER+ breast 
cancer is the expression of the estrogen receptor. IHC analysis shows that ER expression levels 
can range from 1 to 100 % and this can impact the response to endocrine therapies as ER 
negative cells would not be affected by the treatment (Iwamoto et al. 2012; Groenendijk et al. 
2019). The advent of next generation techniques allowed for a deeper analysis of clonality both 
in terms of genetics and epigenetics. Multi-regional DNA sequencing has revealed the presence 
of a high-level subclonal diversity both in primary and relapsing tumors. While no specific 
temporal genetic pattern was revealed, some subclonal mutation detectable before 
chemotherapeutic treatment were found enriched in the relapsing tumor, proving the selection 
of resistant clones (Yates et al. 2015). Single cell resolution techniques added further resolution 
in the analysis of resistance. Indeed an in vivo study in TNBC patients revealed the presence of 
pre-existing clones with genetic characteristic that are selected after chemotherapy 
administration, while the expression profiles are acquired in response to the drug (Kim et al. 
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2018). In contrast a recent in vitro study in MCF7 revealed that pre-existent clones with specific 
expression profiles are selected during chemotherapy administration (Prieto-Vila et al. 2019).  
In the context of endocrine therapy, only few studies tried to address the role of clonality in 
resistance. A barcoding approach used in vitro to track single clones of MCF7 during tamoxifen 
and fulvestrant resistance development revealed a selection of specific pre-existing clones. The 
resistant clones were described to arise from around 1% of the initial population and specific 
genetic variants were associated with the clonal selection (Hinohara et al. 2018). A different 
study approached the issue of clonality in the tumors mapping the epigenetic status of tumors 
with ChIP, with a focus on the role of enhancers in tumor heterogeneity. Their results show that 
the administration of the therapy itself drives the selection of non-genetically defined clones 
(Patten et al. 2018). Thus, the understanding of the role of clonal heterogeneity in breast 
cancer and its impact on endocrine therapy administration is still evolving. More studies are 
needed to establish the role of epigenetic and genetics in the selection or adaptation of 
resistant clones and define the exact mechanism that drives selection for specific drugs. 
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2. Aims of the study 
Resistance to endocrine therapy in breast cancer is an urgent clinical problem that affects 
around 40% of all patients treated with this therapy. To address this question in an in vitro 
setting, researchers developed cellular models of endocrine therapy resistance. In literature, 
the strategy to identify the mechanisms of resistance development and novel targets involved 
in the process has focused on the differences between resistant and sensitive cells. Even 
though some progresses have been made and new targeted drug are now available to treat 
resistant breast cancer, mortality rate for these patients remains high. Additionally there is a 
lack of understanding of the role of clonality in the tumors and how the initial heterogeneity 
might affect treatment outcome. The aim of this PhD thesis was to address these issues related 
to the mechanisms of endocrine therapy resistance development with two different 
approaches: 
1) Time-resolved profiling of resistance development for identification of novel drivers: 
a. Generation of cell lines resistant to tamoxifen treatment and to estrogen deprivation 
b. Profiling of the cell lines during resistance development to identify the timing of changes 
in gene expression, methylation and acetylation  
c. Identification of target genes driving early stages of resistant development 
d. Validation of the role of a selected target in resistance-associated phenotypes in vitro 
with knock-down, knock-out and over-expression approaches 
e. Investigation of the mechanisms by which the candidate gene regulates resistance  
f. Confirmation of the role of the selected target in vivo in a xenograft model 
g. Correlation of the in vitro generated data to patients’ datasets to add clinical relevance 
to the findings.  
 
2) Barcoding of cell lines to investigate the role of clonality, selection and stochasticity in 
endocrine therapy resistance: 
a. Generation of barcoded cell lines and induction of resistance 
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b. Sequencing of barcodes to identify the mechanism of resistant clones selection 
c. Comparison between treatments (tamoxifen and estrogen deprivation) and cell lines 
(MCF7 and T47D) 
d. Correlation of barcode composition to pathway activation analysis 
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3. Materials and Methods 
3.1. Materials 
3.1.1 Instruments 
Aushon 2470 contact printer Aushon / Quanterix 
Bacterial Incubator (37°) Memmert 
Bacterial shaking Incubator (37°) INFORS HT 
Bioanalyzer Agilent 
Biohit Proline multichannel pipette Sartorius  
Bioruptor Plus sonication device Diagenode 
Cell culture hood HERA Safe  Thermo Fisher Scientific  
Cell culture incubators  Heraeus  
Binder  
Centrifuges  Eppendorf AG 
Heraeus 
Hettich  
DNA gel apparatus Renner  
Flow Cytometer FACS Calibur  Becton Dickinson  
Fluorescent microscope Axiovert 40 CFL Carl Zeiss 
Freezer (-20°) Liebherr 
Freezer (-80°) Sanyo 
Fridge (+4°) Liebher 
Gel documentation system  Herolab  
Glomax explorer plate reader  Promega  
Light Microscope Hund Wetzlar 
LSM 800 Confocal Microscope Carl Zeiss 
Magnetic Stand Thermo Fisher Scientific 
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Molecular Devices Microscope IXM XLS  Molecular Devices  
Nanodrop ND-1000 spectrophotometer  Thermo Fisher Scientific  
Neubauer chamber BRAND 
Odyssey Infrared Imaging System  Li-Cor Biosciences  
Pipetboy acu pipette INTEGRA Biosciences  
Pipetman pipette Gilson  
Power Supply GPS 200/400 Pharmacia LKB 
Protein Gel Apparatus MiniProtean II  Bio-Rad  
Qubit Fluorometric Quantification Thermo Fisher Scientific 
SW41 Ti Rotor and Tubes  Beckman Coulter  
Sequence Detection System ABI 7900HT Applied Biosystems 
Quantstudio 5 Real-Time PCR System Thermo Fisher Scientific 
Thermocycler  Applied Biosystems  
Thermomixer Eppendorf AG 
Titramax 100 rocking platform Heidolph  
Trans-Blot turbo Transfer  Bio-Rad  
Vacusafe INTEGRA Biosciences  
Vortex mixer  NeoLab  
Water Bath Julabo 
 
3.1.2 Chemicals and Reagents 
7-Aminoactinomycin D (7-AAD) BD Biosciences 
Anisomycin Biomol 
Bromodeoxyuridine (BrdU)  BD Biosciences 
BSA Sigma-Aldrich 
β-estradiol Sigma-Aldrich 
cOmplete Mini Protease Inhibitor Roche Diagnostics 
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Cocktail 
Charcoal Stripped Fetal Bovine Serum Sigma-Aldrich 
Dynabeads Protein A Thermo Fischer Scientific 
Dynabeads Protein G Thermo Fischer Scientific 
DMSO Sigma-Aldrich  
DMEM medium Gibco 
EDTA  Sigma-Aldrich  
EGTA Sigma-Aldrich 
Ethanol  Sigma-Aldrich  
Fast Green FCF Carl Roth 
Fetal Bovine Serum Gibco 
Formaldehyde solution 37% Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Glycin Sigma-Aldrich 
Hepes Sigma-Aldrich 
Hoechst 33258 Sigma-Aldrich 
IGEPAL Sigma-Aldrich 
Isopropanol  Greiner Bio-One International  
KOH Sigma-Aldrich 
LiCl Sigma-Aldrich 
Lipofectamine RNAiMAX Thermo Fischer Scientific 
Lipofectamin CRISPRMAX Cas 9  Thermo Fischer Scientific 
L-glutamine, 200mM  Gibco  
Methanol  Greiner Bio-One International  
M-PER mammalian protein extraction 
reagent 
Thermo Fischer Scientific  
NaCl  VWR International  
Na-deoxycholate Sigma-Aldrich 
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NaOH  Sigma-Aldrich  
N-lauroylsarcosine Sigma-Aldrich 
non-DEPC treated nuclease-free water  Thermo Fisher Scientific  
Opti-MEM medium Gibco 
PBS  Gibco 
Paraformaldehyde 16% Thermo Fisher Scientific 
PhosSTOP Phosphatase Inhibitor Cocktail Roche Diagnostics 
Protein Marker Precision Plus Protein 
Dual Color 
BioRad 
Penicillin/Streptomycin Gibco 
Proteinase K  Sigma-Aldrich  
RIPA Lysis and Extraction buffer Thermo Fisher Scientific 
RNAiMax  Invitrogen 
Rockland Blocking Buffer Rockland Immunochemicals Inc.  
Roti-Load 1, 4x sample loading buffer Carl Roth 
SDS  Carl Roth  
siRNAs  Dharmacon, Thermo Fisher Scientific  
Sodium pyruvate, 100mM  Gibco  
SPRIselect beads Beckman Coulter 
TITANIUM Taq DNA Polymerase Takara Bio 
NaF Sigma-Aldrich 
Na2VO4 Bernd Kraft 
TaqMan Fast Universal PCR Master Mix 
(2x)  
Applied Biosystems  
TGFß2 Recombinant Protein  R&D Systems 
Trypsin EDTA Solution (0.25%) Gibco  
Tris HCl  Sigma-Aldrich 
Tris-base  Sigma-Aldrich 
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Triton X-100  Sigma-Aldrich  
Tween 20  Sigma-Aldrich  
T-PER tissue protein extraction reagent Thermo Fischer Scientific  
(Z)-4-Hydroxytamoxifen ≥98% Sigma-Aldrich 
 
3.1.3 Assay Kits 
Annexin V: PE Apoptosis Detection Kit BD Bioscience 
BCA Protein Assay Kit  Thermo Fisher Scientific  
cDNA Synthesis Kit  Thermo Fisher Scientific  
CellTiter-Glo Luminescent assay Promega 
Cytofix/Cytoperm BD Biosciences 
DNeasy Blood & Tissue kit  Qiagen  
DuoSet Ancillary Reagent Kit 2 R&D Systems 
Human TGF-beta 2 DuoSet ELISA R&D Systems 
Infimium MethylationEPIC BeadChip Illumina 
Qubit dsDNA HS Assay Kit Thermo Fisher Scientific 
Rnase free Dnase Set Qiagen 
RNeasy Mini kit  Qiagen  
qPCR MasterMix (RT-QP2X-03+NR)  Eurogentec  
RevertAid™ H Minus First Strand cDNA 
synthesis kit  
Thermo Fisher Scientific 
Wizard SV Gel and PCR Clean-up System Promega 
 
3.1.4 Consumables 
Micro centrifuge tubes (1,5 and 2ml)  Eppendorf AG  
Petri dishes (100 and 150mm) Techno Plastic Products (TPP)  
Conical tubes (15 and 50ml) Becton Dickinson 
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Multi-well plates (6, 12, 24, 48 wells) Thermo Fisher Scientific  
96-well plate transparent  Becton Dickinson  
96-well plate black  Greiner Bio-One International GmbH  
96-well plate white  PerkinElmer  
96-well Clear V-Bottom Deep Well Plate Corning 
Adhesive Plate Seal  Thermo Fisher Scientific  
AMICON® Ultra-4 filtration units  Merck Millipore  
BioCoat Matrigel Invasion Chambers Corning 
Cell Culture Flasks, T-25, T-75, T-175  Techno Plastic Products (TPP) 
Cell Scraper  Corning  
Cry vials 1.8mL  Thermo Fisher Scientific  
FACS tubes Corning 
Filter tips, 10μL, 20μL, 200μL, 1000μL  Neptune  
Matrigel Invasion Chambers Corning 
Mini-PROTEAN TGX Precast Gels BioRad 
Oncyte Nitrocellulose Film-Slide Grace Bio-Labs  
Optical 384 wells plates for Taqman Applied Biosystems 
PCR strips  Steinbrenner Laborsysteme GmbH  
PVDF membrane Immobilon-P  Merck Millipore  
Qubit Assay tubes Thermo Fisher Scientific 
Reservoirs 50ml Corning 
Round-Bottom polypropylene tubes 5ml Thermo Fisher Scientific 
Serological pipettes 2.5mL, 5mL, 10mL, 
25mL, 50ml  
Becton Dickinson  
Stainless steel beads 5ml Qiagen 
Trans-well system (8.0μm pore size)  Corning  
Tips for micropipettes Starlab 
Trans-Blot Turbo mini PVDF Transfer Kit BioRad 
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3.1.5 Software 
Easeq http://easeq.net 
Flowjo v10 Becton Dickinson 
GenePix Pro v7.0 Molecular Devices 
GraphPad Prism v5  GraphPad Software, Inc.  
Image J  NIH 
Inkscape Software Freedom Conservancy, Inc.  
Molecular Devices Analysis Software  Molecular Devices  
Odyssey v2.1  LI-COR  
QuantStudio Design and Analysis Agilent Technologies 
Roche UPL Design Center Roche Diagnostics  
SDS v2.2  Applied Biosystems  
Tinn-R Rgui Team 
 
3.1.6 Databases and datasets 
Ensembl (release 91) EMBL-EBI 
Human GRCh37/hg19 UCSC Genome browser 
MSigDB Broad Institute 
GSE111563 Geo DataSets 
GSE80077 Geo DataSets 
GSE20181 Geo DataSets 
GSE55374 Geo DataSets 
GSE10281 Geo DataSets 
GSE59515 Geo DataSets 
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3.1.7 Buffers and solutions  
ChIP  
Lysis Buffers 
(1/2/3) 
50mM Hepes-KOH 
150mM NaCl 
1mM EDTA 
10% Glycerol 
0.5% IGEPAL 
0.25% Triton X-100 
1x Protease Inhibitor 
Cocktail 
10mM Tris-HCl 
200mM NaCl 
1mM EDTA 
0.5mM EGTA 
1x Protease 
Inhibitor Cocktail 
10mM Tris-HCl 
100nM NaCl 
1mM EDTA 
0.5mM EGTA 
0.1% Na-Deoxycholate 
0.5% N-lauroylsarcosine 
1x Protease Inhibitor 
Cocktail 
Elution Buffer 
50mM Tris-HCl 
10mM EDTA 
1% SDS 
TE Buffer 
M-PER lysis buffer 
1x Complete Mini Protease Inhibitor Cocktail 
1x PhosSTOP Phosphatase Inhibitor Cocktail 
Washing buffer PBS with 0.5% BSA 
ELISA 
Blocking buffer  PBS with 1% BSA 
Washing buffer PBS with 0.25% Tween 20 
RPPA and WB 
Blocking buffer  
1:1 Rockland blocking buffer: TBS 
1 mM Na3VO4 
10 mM NaF 
FCF staining 
solution 
0.005% Fast Green FCF 
10% Acetic acid 
30% Ethanol 
FCF destaining 10% Acetic acid, 
 
49 
 
solution 30% Ethanol 
Protein Lysis buffer 
M-PER lysis buffer 
1x Complete Mini Protease Inhibitor Cocktail 
1x PhosSTOP Phosphatase Inhibitor Cocktail 
6x SDS buffer 
 
10% Glycerol 
4% SDS 
10 mM DTT 
125 mM Tris–HCl pH 6.8 
SDS running buffer 
192 mM glycine 
25 mM Tris 
0.1% SDS 
10X TBS 1.37M NaCl, 200mM Tris, pH 7.6 
1X TBST 0.1% Tween 20 in 1x TBS 
Transfer buffer 
20% Trans-BlotR Turbo™ 5x Transfer Buffer 
20% EtOH 
60% H2O 
 
 
3.1.8 Antibodies 
PRIMARY ANTIBODIES 
Target Antibody ID Company Species 
4E-BP1 CST 9644 Cell Signaling rabbit 
AKT CST 9272 Cell Signaling rabbit 
ATF3 ab207434  Abcam rabbit 
β-Actin Actin- Clone4 MP Biomedicals mouse 
β-Catenin CST 9562 Cell Signaling rabbit 
CSNK2B sc 12739 Santa Cruz mouse 
c-RAF CST 9422 Cell Signaling rabbit 
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CSNK1A1 CST 2655 Cell Signaling rabbit 
CSNK1E CST 12448 Cell Signaling rabbit  
CTNNBIP1 ab 129011 Abcam rabbit 
Dishevelled 3 ab 76081 Abcam rabbit 
DKK1 WH0022943M1 Sigma mouse 
EGFR CST 2232 Cell Signalling rabbit 
ERBB2 MS-730 Thermo scientific mouse 
ERBB4 ab76303 Abcam rabbit 
ERK1 RnD AF1575 R&D rabbit 
FAK CST 3285 Cell Signaling rabbit 
GAB1 CST 3232 Cell Signaling rabbit 
GRB2 CST 3972 Cell Signaling rabbit 
GSK-3alpha CST 9338 Cell Signaling rabbit 
GSK-3beta CST 9315 Cell Signaling rabbit 
ERBB3 CST 12708 Cell Signaling rabbit 
JNK1 CST3708 Cell signalling mouse 
LKB1 CST 3050 Cell Signaling rabbit 
LRP5 CST 5731 Cell Signaling rabbit 
MEK1 BD 610122 BD Biosciences mouse 
MSK1 AF2518 R&D goat 
MSK2 CST 3679 Cell Signaling rabbit 
mTOR CST 2972 Cell Signaling rabbit 
NF-kappaB p65 CST 8242 Cell Signaling rabbit 
p38 MAPK  CST9212 Cell Signaling rabbit 
P44/42 CST9102 Cell Signaling rabbit 
p70 s6 kinase CST 2708 Cell Signaling rabbit 
PAK1 CST 2602 Cell Signaling rabbit 
PAK2 ab76293 Abcam rabbit 
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PDK1 CST3062 Cell Signaling rabbit 
Phospho-4E-BP1_Thr37_Thr46 CST 2855 Cell Signaling rabbit 
Phospho-Akt_Ser473 CST 9271 Cell Signaling rabbit 
Phospho-beta-Catenin_Ser675 CST 9567 Cell Signaling rabbit 
Phospho-c-Jun_Ser73 CST 9164 Cell Signaling rabbit 
Phospho-c-Raf_Ser259 CST 9421 Cell Signaling rabbit 
Phospho-elF4B _Ser406 CST 5399 Cell Signaling rabbit 
Phospho-GSK-3beta_Ser9 CST 9323 Cell Signaling rabbit 
Phospho-JNK Thr183_Tyr185 CST 4668 Cell Signaling rabbit 
Phospholipase C gamma ab 41433 Abcam mouse 
Phospho-LKB1_Ser428 CST 3482 Cell Signaling rabbit 
Phospho-MEK1_Ser298 CST 9128 Cell Signaling rabbit 
Phospho-NF-kappaB p65_Ser536 CST 3033 Cell Signaling rabbit 
Phospho-p38 MAPK_Thr180-
Tyr182 
CST 9215 Cell Signaling rabbit 
Phospho-p44/42 MAPK_ERK1-
2_Thr202-Tyr204 
CST 4370 Cell Signaling rabbit 
Phospho-p70 S6 Kinase_Thr389 CST 9234 Cell Signaling rabbit 
Phospho-p90RSK_Ser380 CST 9341 Cell Signaling rabbit 
Phospho-PDK1_Ser241 CST 3061 Cell Signaling rabbit 
Phospho-PLCgamma1_Ser1248 CST 4510 Cell Signaling rabbit 
Phospho-PRAS40_Thr246 CST 2997 Cell Signaling rabbit 
Phospho-PTEN_Ser380_Thr382-
383 
ab 109454 Abcam rabbit 
Phospho-S6 Ribosomal 
Protein_Ser235-236 
CST 4858 Cell Signaling rabbit 
Phospho-Src Family_Tyr416 CST 2101 Cell Signaling rabbit 
PI3 Kinase p110 beta ab 32569 Abcam rabbit 
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PI3 Kinase p110alpha CST 4249 Cell Signaling rabbit 
PI3 Kinase p85 alpha ab 40755 Abcam rabbit 
PKCdelta CST 9616 Cell Signaling rabbit 
PRAS40 CST 2691 Cell Signaling rabbit 
RSK1 CST 8408 Cell Signalling rabbit 
S6 Ribosomal Protein CST 2217 Cell Signaling rabbit 
SOS CST 12409 Cell Signalling rabbit 
SRC CST 2123 Cell Signaling rabbit 
SECONDARY ANTIBODIES 
F(ab')2-Goat anti-Rabbit IgG (H+L) Cross-Adsorbed 
Secondary Antibody, Alexa Fluor 680 
A21077 Thermo Fisher Scientific 
F(ab')2-Goat anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor 680 
A21059 Thermo Fisher Scientific 
Rabbit anti-Goat IgG (H+L) Cross-Adsorbed 
Secondary Antibody, Alexa Fluor 680  
A21088 Thermo Fisher Scientific 
 
3.1.9 siRNAs 
siRNA Annotation Target Sequence 
ON-TARGETplus control 
siRNA 
siCTRL UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCCUA 
UGGUUUACAUGUUUUCUGA 
ON-TARGETplus TGFB2 
siRNA 
siTGFB2 GGAUUGAGCUAUAUCAGAU 
CUGCGUGUCCCAAGAUUUA 
GAUGCGGCCUAUUGCUUUA 
GAGCAUGCCCGUAUUUAUG 
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ON-TARGETplus ATF3 
siRNA 
siATF3 GGUUUGCCAUCCAGAACAA 
CAGUGGUGUUUGAGGAUUU 
GCGACGAGAAAGAAAUAAG 
AGACGGAGUGCCUGCAGAA 
 
3.1.10 PCR Primers 
Gene Primer Left Primer Right Probe 
ATF3 TTTGCCATCCAGAACAAGC CATCTTCTTCAGGGGCTACCT 53 
ACTB ATTGGCAATGAGCGGTTC GGATGCCACAGGACTCCA 11 
RPS6KA5 GAAATGGATCCCACTTATTCTCC CAACAAAGGAATAGCCCTGAA 43 
DUSP1 CGAGGCCATTGACTCATAGA CTGGCAGTGGACAAACACC 65 
DUSP10 TGAATGTGCGAGTCCATAGC TGGCAATTCAAGAAGAACTCAA 22 
JUN CCAAAGGATAGTGCGATGTTT CTGTCCCTCTCCACTGCAAC 19 
TGFB2 CCAAAGGGTACAATGCCAAC CAGATGCTTCTGGATTTATGG 67 
BAMBI CGCCACTCCAGCTACATCTT CACAGTAGCATCGAATTTCACC 71 
ERBB2 GGGGAAACCTGGAACTCACCT AGCGATGAGCACGTAGCC 4 
 
3.1.11 sgRNAs 
Gene Annotation Sequence 
ATF3 KO1 AAAGUGCCGAAACAAGAAGA 
ATF3 KO2 AGAAGGCACUCACUUUCUGC 
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3.2. Methods 
3.2.1 Cell Culture  
3.2.1.1 Cell cultivation 
All parental breast cancer cells were obtained from ATCC. MCF7-TAMR (tamoxifen resistant) 
and MCF7-LTED (Long-Term Estrogen Deprived) were kindly provided by Dr. Luca Magnani form 
Imperial College London (ICL). Cell lines were regularly sent for cell line authentication to 
Multiplexion GmbH and tested for mycoplasma contamination. The cell lines were cultured in 
the respective media (Table 2) and incubated at 37oC with 5% CO2 in a humidified atmosphere. 
Cells were passaged when they reached 80% confluency under aseptic conditions in a laminar 
air-flow hood.  
Table 2: Cell lines 
Cell line Source Characteristics Growth media 
MCF7 ATCC HTB-22 
Luminal A breast 
cancer cell line 
DMEM + 10% FBS + 1% 
P/S + 10
-8
M 17-ß-estradiol 
(E2) 
T47D  ATCC HTB-133 
MCF7-T 
Dr. Luca Magnani, 
ICL 
Resistant to 100nM 
TAM 
DMEM + 10% FBS + 1% 
P/S + 100nM TAM (TAM) 
T47D-T  Derived from T47D 
MCF7-L  
Dr. Luca Magnani, 
ICL Resistant to long-
term estrogen 
deprivation 
DMEM - phenol red + 10% 
charcoal stripped FBS + 1% 
P/S + 1% Glutamine + 1% 
Sodium Pyruvate 
T47D-L  Derived from T47D 
MCF7 ATF3-KO1 
Derived from MCF7 
 
ATF3 Crispr-Cas9 
KO 
DMEM + 10% FBS + 1% 
P/S + 10
-8
M 17-ß-estradiol 
(E2) 
MCF7 ATF3-KO2 
MCF7 Empty Derived from MCF7 
 
pLX304 – empty DMEM + 10% FBS + 1% 
P/S + 10
-8
M 17-ß-estradiol + 
Blasticidin S 
MCF7 ATF3 OE pLX304 – ATF3 
T47D Empty 
Derived from T47D 
pLX304 – empty 
T47D ATF3 OE pLX304 – ATF3 
MCF7-T shSCR Derived from MCF7-T pLKO.1 - Scramble DMEM + 10% FBS + 1% 
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 P/S + 100nM tamoxifen 
(TAM) + Puromycin 
MCF7-T shATF3_1 
pLKO.1 - 
TRCN0000013570 
MCF7-T shATF3_2 
pLKO.1 -  
TRCN0000013572 
T47D-T shSCR 
Derived from T47D-T 
pLKO.1 - Scramble 
 
T47D -T shATF3_1 
pLKO.1 - 
TRCN0000013570 
T47D -T shATF3_2 
pLKO.1 -  
TRCN0000013572 
MCF7-L shSCR 
Derived from MCF7-L 
pLKO.1 - Scramble 
 
DMEM - phenol red + 10% 
charcoal stripped FBS + 1% 
P/S + 1% Glutamine + 1% 
Sodium Pyruvate + 
Puromycin 
MCF7-L shATF3_1 
pLKO.1 - 
TRCN0000013570 
MCF7-L shATF3_2 
pLKO.1 -  
TRCN0000013572 
T47D-L shSCR 
Derived from T47D-L 
pLKO.1 - Scramble 
 
T47D -L shATF3_1 
pLKO.1 - 
TRCN0000013570 
T47D -L shATF3_2 
pLKO.1 -  
TRCN0000013572 
MCF7 barcoded Derived from MCF7 ClonTracer 
barcoding Library 
 
DMEM + 10% FBS + 1% 
P/S + 10
-8
M 17-ß-estradiol + 
Puromycin 
T47D barcoded Derived from T47D 
 
Briefly, cells were washed with PBS and incubated with 0.25% trypsin-EDTA at 37oC. Once the 
cells detached, full growth medium was added to neutralize the trypsin. The cells were counted 
using a Neubauer cell counting chamber and seeded in the appropriate cell number for further 
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expansion or experiments (Table 3). Parental cells were used for experiments up to passage 
number 25. 
Table 3: Cells plating conditions 
Cell line Culture conditions Experimental conditions 
All cell lines 
25 cm
2 flasks: 5x10
5
 cells 
75 cm
2
 flasks / 10cm dishes: 1x10
6
 cells 
150 cm
2
 flasks / 15cm dishes: 2x10
6
 cells 
 
6 wells: 1x10
5
 cells 
12 wells: 5x10
4
 cells 
24 wells: 2,5x10
4
 cells 
96 wells: 5x10
2
 cells 
 
Frozen cell stocks were generated by centrifuging cells at 1200 rpm and re-suspending cell 
pellets in full growth medium supplemented with 10% FBS and 10% DMSO. Cells were aliquoted 
in 1.5ml cryo-vials and cooled down in isopropanol bath at -80oC for short term storage and 
then transferred to liquid nitrogen containers for long term storage. 
Frozen vials of cells were recovered by thawing in a 37oC water bath and the cell suspension 
was centrifuged at 1200 rpm to remove the remaining DMSO. Cells were then seeded in a dish 
or flask and allowed to attach overnight before changing the media. 
 
3.2.1.2 Generation of resistant cell lines 
Parental sensitive T47D were cultured for 1 year in the presence of 100nM tamoxifen or in 
estrogen deprivation to obtain T47D-TAMR and T47D-LTED respectively. The cells were 
passaged when they reached 80% confluency or reseeded in a new dish if they were not 
reaching confluency for more than 4 weeks. In this case, the medium was changed every week 
to ensure availability of nutrient. Two independent resistance acquisitions were performed in 
parallel therefore generating two replicates of resistant cell lines. 
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3.2.1.3 Generation stable cell lines 
Stable cell lines were generated in the Stable isogenic cell line core facility at the DKFZ. Briefly, 
HEK293FT cells were co-transfected with the lentiviral constructs (pLX-304 vector with/without 
ATF3 ORF, pLKO.1 with shSCR/shATF3 or pRSI9-U6 with the ClonTracer library) and 2nd 
generation viral packaging plasmids VSV.G (Addgene #14888) and psPAX2 (Addgene #12260). 
48h after transfection, virus containing supernatant was removed and cleared by centrifugation 
(5min/500g). MCF7 and T47D cells were transduced with lentiviral particles at 70% confluency 
in the presence of 10 μg/ml polybrene. For the ClonTracer library (Addgene #67267) 
transduction, an MOI (Multiplicity Of Infection) of 0.05 was used to ensure the delifery of a 
single barcode per cell. Considering that the number of cell receiving a viral particle follows a 
Poisson distribution, with an MOI of 0.05 there will be: 
 
                  0.0475 cells infected with 1 barcode 
                       0.001 cells infected with more than 1 barcode 
               0.951 cells not infected 
 
24h after transduction virus containing medium was replaced with selection medium for the 
respective constructs in S2 lab conditions and cells were provided by the core facility and 
transferred to S1 lab conditions. Transduced cells were selected with the specific antibiotic 
(puromycin or blasticidin) and kept constantly in the selection medium.  
 
3.2.1.4 siRNA transfections 
Cells were seeded as stated before. Transfections were performed the day after seeding with 
RNAiMax® according to manufacturer’s instructions. siRNAs were used at a final concentration 
of 30nM. Before the siRNA transfection, the medium was changed to growth media without 
P/S. Following the volumes indicated in Errore. L'origine riferimento non è stata trovata. a pre-
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mix of RNAiMax and Opti-MEM was prepared, and siRNAs were diluted in Opti-MEM. The siRNA 
and RNAiMax pre-mix were mixed, incubated for 5min and then added to the cells. Cells were 
then incubated in 37o C, 5% CO2 humidified atmosphere for different time points depending on 
the assay being performed. 
 
Table 4: Volumes of reagents used for siRNA transfections 
Plate 
Format 
P/S-free 
medium 
Lipofectamine 
RNAiMAX 
Opti-
MEM 
siRNA Opti-MEM 
siRNA mix 
added  
6-well 960 5 115 18 102 240 
12-well 480 2,5 57,5 9 51 120 
24-well 240 1,25 28,75 4,5 25,5 60 
96-well 80 0,416 9,583 1,5 8,5 20 
 
 
3.2.1.5 Crispr/Cas9 transfections 
ATF3 knockout clones were generated with CRISPR/Cas9 technology using two sgRNAs 
targeting exon 4 of the ATF3 gene. Cells were seeded at 60% confluency and were transfected 
the following day according to manufacturer’s instructions with Lipofectamin CRISPRMAX Cas9 
transfection reagent. After 3 days the cells were detached and seeded in a 96-well plate at a 
dilution of 0.8 cells/well to obtain single clones. The media was changed every week to ensure 
availability of nutrient and the single-cell derived clones were moved to bigger wells when 
confluent. When the clones had reached a 6 well plate format they were screened for the 
presence of the editing both at the DNA level with Sanger sequencing and at the protein level 
with Western Blot. 
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3.2.2 Analysis of RNA expression 
3.2.2.1 RNA isolation and reverse transcription 
mRNA was isolated and purified using the “RNeasy Mini” Kit from Qiagen according to 
manufacturer’s instructions and the RNA was eluted in 80µl of nuclease free water. RNA 
concentration was measured with NanoDrop-ND 1000. 500ng of RNA was used to synthesize 
the cDNA using the RevertAid H Minus First Strand Reverse Transcription Kit. RNA was mixed 
with 1 μl of Oligo(dT) primer to a volume of 12 ul. After 5 minutes incubation at 70°C, 4 μl of 5x 
Reaction Buffer, 1 μl of RiboLock Ribonuclease Inhibitor, 2 μl of dNTP mix (10 mM) and 1 μl of 
RevertAid H Minus-MuIV Reverse Transcriptase, were added to the RNA. The cDNA was 
synthesised using following PCR programme:     
5 min - 37°C 
60 min - 42°C 
10 min - 70°C 
 
3.2.2.2 Quantitative RT PCR 
The cDNA was diluted to 2 ng/ μl with nuclease free water and 5 μl were used for the Taqman 
RT-PCR assay. For each sample the master mix for one gene included 5,5 μl of primaQUANT 
real-time PCR Master Mix, 0.11µl of forward primer, 0.11µl reverse primer, 0.11µl Taqman 
probe and 0,17 μl water. 6µl of the mix was pipetted with 5 μl of cDNA into 384 well plates in 
triplicates. The plate layout was prepared on the SDS or QuantStudio software and the 
following qPCR program was used: 
 2 min - 50°C 
15 min - 95°C 
15 sec - 95°C    
60 sec - 60°C    
 
The data were analysed using the SDS or QuantStudio software with the ΔΔCt method. The Ct 
values were normalized to housekeeping gene ACTB. 
45 cycles 
cycles 
 
60 
 
3.2.2.3 RNA sequencing 
RNA sequencing (RNA-seq) was performed using HiSeq 4000 Paired-End 100 base pair in the 
Genomics and Proteomics Core Facility at the DKFZ. Data analysis was performed by Maryam 
Soleimani and Dr. Perry Moerland from the University of Amsterdam (UvA). Briefly, raw 
sequencing data were subjected to quality control using FastQC and trimmed using 
Trimmomatic (v0.32). Reads were aligned to the human reference genome (hg38) using HISAT2 
(v2.0.4). Gene level counts were obtained using HTSeq (v0.6.1) and the human GTF from 
Ensembl (release 85). Statistical analyses were performed using the edgeR and limma 
R/Bioconductor packages. Genes with more than 5 counts in 1 or more samples were retained. 
Count data were transformed to log2-counts per million (logCPM) with a prior count of 3 and 
normalized by applying the trimmed mean of M-values method. 
Gene-wise linear models were fitted with coefficients for each combination of treatment (+E2, 
+TAM, -E2) and time point and a coefficient to correct for systematic differences between the 
two biological replicates. For both LTED and TAM treated samples, contrasts were made 
between each individual time point t and the WT cell line, that is, (-E2t) – untreated0 and 
(+TAMt) – untreated0, respectively. Differential expression was assessed using empirical Bayes 
moderated statistics with an intensity-dependent trend fitted to the prior variances. Resulting 
p-values were corrected for multiple testing using the Benjamini-Hochberg false discovery rate 
(FDR). Genes that changed in at least one time point compared to E2 were selected based on 
their moderated F-statistics and corresponding FDR<0.1 (-E2) or FDR<0.25 (+TAM). Additional 
gene annotation was retrieved from Ensembl (release 91) using the biomaRt R/Bioconductor 
package. 
 
3.2.3 Analysis of protein expression 
3.2.3.1 Protein extraction and quantification 
Before harvesting the proteins cells were washed once with cold PBS. The amount of lysis 
buffer added was based on the plate size (40 µl for 6well plates, 100 µl for 100 mm dishes) and 
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the cells were detached using a cell scraper. Cells were incubated on ice with the lysis buffer for 
30 min, vortexing them every 10 min and proteins were separated by centrifuging the samples 
at 13000 rpm for 10 min. Lysates were stored at -80oC or used directly.  
Protein concentrations were determined using the BCA Protein Assay Kit according to 
manufacturer’s instructions. Briefly, BSA standards of different concentrations were prepared 
by diluting BSA in PBS. 25µl of each standard and 5µl of each sample was pipetted into a 96-
well microplate in duplicates. The BCA reagent was prepared freshly by mixing Reagent A and 
Reagent be in a 50:1 ratio. 200µl of the mix was then added to each well of the microplate. The 
plate was protected from light and incubated at 37oC for 40 min. After the incubation the 
absorbance at 562nm was measured with the Glomax explorer plate reader. 
Based on the BSA standard, a standard curve was prepared and protein concentrations of the 
samples were calculated from this curve.  
 
3.2.3.2 Western Blot 
Samples were prepared for gel electrophoresis by mixing the lysates with 4x RotiLoad in a 1:4 
dilution and water to obtain 30 µg as a final protein amount. The samples were then heated at 
95oC for 5min to denature the proteins. In the meantime the Mini-PROTEAN TGX Precast Gels 
were loaded into the MiniProtean gel apparatus filled with 1x running buffer. After the removal 
of the comb, the gel were loaded with 3 µl molecular weight marker and 15, 20 or 50 µl of 
sample based on the gel size (15, 12 or 10 wells respectively). Electrophoresis was performed at 
145V for 60min. 
After protein separation via SDS-PAGE, the proteins were transferred to a PVDF membrane 
using the Trans-BlotR Turbo Transfer System accordance to manufacturer’s instruction. The 
membrane was then blocked for 2h at RT with Rockland blocking buffer and subsequently 
incubated with a target specific primary antibody diluted in blocking buffer ON at 4°C on a 
rocking platform. The membrane was washed 3x 10 min in TBST followed by a 1h incubation 
with Alexa Flour 680 conjugated secondary antibody. After washing again for 3x 10 min in TBST, 
 
62 
 
the membrane was scanned at an excitation wavelength of 685 nm and a resolution of 84 µm 
using the Odyssey Infrared Imaging System. 
 
3.2.3.3 Reverse Phase Protein Array 
The lysates were adjusted to a total protein concentration of 2 µg/µl. Samples were mixed with 
6x SDS Buffer and denatured at 95°C for 5min. The lysates were then pipetted into 348-well 
plates and centrifuged for 2min at 1200 rpm. As internal controls a dilution series of cell line 
pools were created using 4 different samples starting from a concentration of 2.5 µg/µl. All 
samples were printed as technical triplicates on Oncyte Avid Nitrocellulose Film-Slides using an 
Aushon 2470 contact printer equipped with 185 µm solid pins. These pins allow to spot 1.6nl of 
sample per spot, with an average spot diameter of 250µm. The humidity during the printing run 
was kept constant at 80%. Slides were stored after the print run at -20°C. After spotting the 
slides were blocked for 2h at RT with filtered Rockland blocking buffer.  
After blocking, the slides were incubated with target-specific primary antibodies at 4°C ON. 
Representative subarrays were incubated without primary antibody and served as “blank” 
control. After incubation the slides were washed 3 x 10 min with TBST and subsequently 
incubated with Alexa Fluor® 680 F(ab')2 fragments of goat anti-mouse IgG or anti-rabbit IgG in 
1:12000 dilution for 1h at RT in the dark. Slides were again washed 3 x 10 min with TBST 
followed by two final washing steps with ultra-pure water for 5min. The slides were then air 
dried. The last slide of each spotting plate was stained using Fast Green FCF protein dye for 
total protein quantification to be used for normalization. All the slides were scanned with an 
excitation wavelength of 685nm and a resolution of 21 µm with the Odyssey® Infrared Imaging 
System and the resulting TIFF images (16 bit) were used for further analysis. 
Signal intensities of individual spots were quantified using GenePixPro 7.0 software. The 
acquired TIFF image of each slide and gene pix array list file obtained from the Aushon spotter’s 
software was matched into a gpr file. A visual inspection of each spot was performed manually 
and slides without uniform background signal were excluded from further analysis. RPPA raw 
 
63 
 
data preprocessing and quality control were performed using the RPPanalyzer R-package 
(Mannsperger et al. 2010). The raw signal intensities of the control samples were plotted 
against the respective total protein concentration. Only antibodies showing a linear correlation 
between target signal intensity and protein concentration were used for further analysis. Next, 
target signals were normalized to the total protein amount per spot via FCF control. After 
median calculation of technical replicates, normalized target signal intensities were plotted 
against the signal intensities obtained by incubation of secondary antibody controls (blank 
signal) and only antibodies with a clear signal above blank levels were kept for the further 
analysis. 
 
3.2.3.4 ELISA 
Enzyme linked immunosorbent assay (ELISA) was used to detect and quantify TGFB2 in the 
supernatant of the cells after perturbations. To this end, Human TGF-beta 2 DuoSet ELISA kit 
was used according to the manufacturer’s instructions. Briefly, a 96-well plate was coated with 
the capture antibody diluted in PBS to its working concentration and incubated ON. The plate 
was then washed with the wash solution and 200 µl of blocking buffer were added to each well 
and the plate was incubated for 2 hours. TGFB2, secreted by the cells in an inactive form, was 
activated by pH change, adding 25 µl of 1N HCl to 125 µl of sample, incubating for 10 minutes 
and increasing the pH again with 1,2 N NaOH/0,5 M HEPES. Subsequently, the plate was 
washed again and 100 µl of the serial standard dilution and all samples were added in duplicate 
and incubated at RT for 2 hours. For the detection, the wells were washed and incubated with a 
biotinylated detection antibody for 2 hours at RT followed by Streptavidin-HRP incubation for 
20 min at RT. The plate was washed again and Substrate Solution, consisting of 1:1 mixture of 
Colour Reagent A (H2O2) and Colour Reagent B (Tetramethylbenzidine), was added to each 
well, followed by another 20 min incubation at RT. Addition of 50 μl of Stop Solution (2 N 
H2SO4) stopped the catalytic reaction and the light absorbance at 450 nm was measured with 
the Glomax Explorer Plate Reader. An additional measurement at 560 nm was performed to 
correct optical imperfections. For the analysis the results of measurement at 560 nm were 
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subtracted from those at 450 nm. The obtained values were used for the calculation of TGFB2 
amount in the media from the standard curve formula. The standard curve was always set in a 
way that R2 > 0.97. All results were normalized to the RNA amount quantified via NanoDrop 
ND-1000 Spectrophotometer and then to the respective control.  
 
3.2.4 Analysis of epigenetic profile 
3.2.4.1 Chromatin Immunoprecipitation  
Cells were harvested by trypsinization and cross-linked with 1% formaldehyde diluted in growth 
media for 10 min at RT. To stop the reaction 520 µl of 2.5M Glycine was added to a final 
concentration of 0.15 M. The cells were incubated for 5 min at RT and pelleted by 
centrifugation at 1200 rpm for 5 min at 4°C. Cells were then washed twice with cold PBS 
followed by centrifugation and the pellets were stored at -80°C until further processing. 
10 µl magnetic beads were pre-washed 3x with 1ml washing buffer and re-suspended in 350 µl 
of washing buffer with 2µg of antibody for each ChIP. The mix was then incubated for 6 hours 
rotating at 4°C. In the meantime the cells were lysed with three lysis buffers. Each time the 
pellet was re-suspended, incubated 10min at 4°C and centrifuged at 2000 rmp 5 min. At the last 
step the cells were re-suspended in 300 µl of lysis buffer 3 and sonicated in the Bioruptor for 
10min with 30 second on/off cycles. After sonication 30 µl 10% Triton X-100 were added and 
the cells were spun down 10 min at 4°C at 13000 rpm. For ChIP-seq application 15 µl were kept 
for input, 5 µl to run on a SDS-PAGE gel to check for fragmentation efficiency and the rest was 
added to 800 µl lysis buffer 3, 90 µl 10% Triton X-100 and incubated with the beads. For ChIP-
PCR application DNA was quantified with the nanodrop and 25 ug of DNA was used for each 
condition. 5 µl of DNA was run on a SDS-PAGE gel to check for fragmentation efficiency. Before 
incubation the beads were washed to remove unbound antibody and re-suspended in 100 µl 
lysis buffer 3 for each ChIP. Both the chromatin sample were incubated ON rotating at 4°C. 
Samples for the gel run were de-crosslinked ON at 65°C with 100 µl of elution buffer. DNA was 
extracted with Phenol-Chloroform and precipitated with NaCl. DNA was then re-suspended in 
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water and loaded in a 1% agarose gel at 70V for 40 minutes. Successful chromatin 
fragmentation was examined under UV light (Figure 5 a) 
  
Figure 5: Validation of ChIP sonication and size selection 
(a) Agarose gel validation of sonication efficacy. 1st lane: 100bp ladder, 2nd lane: sonicated DNA 
from MCF7, 3rd lane: sonicated DNA from T47D. (b) Example of the size selection validation with 
Agilent Bioanalyzer after library preparation 
 
After ON incubation, chromatin samples were washed with 3x 300 µl RIPA and 2x 300 µl TE 
buffer before proceeding to de-crosslink as mentioned above. After ON incubation the beads 
were captured and the supernatant was incubated for 30 min at 37°C with RNAse followed by 1 
hour at 55°C with Proteinase K. To purify the product SPRIselect beads were used according to 
manufacturer’s instructions. For Chip-seq samples were measured with the Qubit dsDNA HS 
Assay Kit according to manufacturer´s instructions. Before construction of ChIP-seq libraries, 
enrichment of the immunoprecipitated sample was ascertained using positive and negative 
controls with ChIP-qPCR. To prepare the libraries for sequencing the NEBNext Ultra DNA Library 
Prep Kit was used according to manufacturer’s instructions. The size distribution was evaluated 
on the Agilent Bioanalyzer with the High sensitivity DNA kit (Figure 5 b). Samples were then 
multiplexed and run on the Next Seq500 75 SR in the BRC Genomic Facility of Imperial College 
London. Bioinformatics pre-processing and peak calling was performed by Giacomo Corleone 
from ICL as previously described (Patten et al. 2018). For ChIP-qPCR purified samples were 
diluted 1:4 in water and a quantitative RT PCR was performed as described in the previous 
chapter.  
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3.2.5 Analysis of barcode composition 
3.2.5.1 PCR amplification and sequencing 
DNA was extracted using the DNeasy Blood & Tissue kit according to manufacturer’s 
instructions. PCR was used to amplify the barcode sequence and introduce Illumina adaptors 
and index sequences for multiplexing (Bhang et al. 2015). The primers used are reported in 
Table 5. Two parallel reactions with 2,5 μg of genomic DNA were used as a template to ensure 
sufficient template coverage. For each sample the master mix included 5 µl of 10X Titanium Taq 
PCR buffer, 1 µl of forward primer, 1 µl reverse primer, 1 µl 50X dNTP (10nM), 1 µl 50X Titanium 
Taq DNA polymeraseand, 2 µl DMSO and water to a volume of 50 µl.  The following PCR 
amplification program was used:  
5 min - 95°C 
30 sec - 95°C 
15 sec - 69°C 
9   sec - 72°C 
7  min - 72°C    
 
The PCR products were cleaned with the Wizard SV Gel and PCR Clean-up System and the final 
concentration and size was evaluated with the Bioanalyzer. 10 samples were multiplexed for 
each lane and sequenced using HiSeq 2000 V4 Single-read 50 base pair in the Genomics and 
Proteomics Core Facility at the DKFZ using the custom sequencing primer TCTACACACTGACTGC-
AGTCTGAGTCTGACAG 
 
Table 5: Barcoding PCR and sequencing primers 
PCR Forward Primer AATGATACGGCGACCACCGAGATCTACACACTGACTGCAGTCTGAGTCTGACAG 
PCR Reverse Primer 1 CAAGCAGAAGACGGCATACGAGATACGATCGTGAGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
PCR Reverse Primer 2 CAAGCAGAAGACGGCATACGAGATCTAGATCGTGGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
30 cycles 
cycles 
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PCR Reverse Primer 3 CAAGCAGAAGACGGCATACGAGATGACTCGATCAGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
PCR Reverse Primer 4 CAAGCAGAAGACGGCATACGAGATTGACTAGCTCGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
PCR Reverse Primer 5 CAAGCAGAAGACGGCATACGAGATATGCTCAGCAGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
PCR Reverse Primer 6 CAAGCAGAAGACGGCATACGAGATCGATCTGCATGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
PCR Reverse Primer 7 CAAGCAGAAGACGGCATACGAGATGATAGCTGACGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
PCR Reverse Primer 8 CAAGCAGAAGACGGCATACGAGATAGTACGCATGGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
PCR Reverse Primer 9 CAAGCAGAAGACGGCATACGAGATGTATCACGACGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
PCR Reverse Primer 10 CAAGCAGAAGACGGCATACGAGATTCGCAGTACTGTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCTAGCACTAGCATAGAGTGCGTAGCT 
 
3.2.5.2 Barcode-composition analysis 
The bioinformatics analysis was performed by Dr. Luca Penso Dolfin (DKFZ). FASTQ files were 
reformatted using fastq_quality_converter from the package fastx_toolkit, using the following 
parameters: -n -Q 33. The resulting files were filtered for a minimum average read quality of 30 
and a minimum quality of 10 at any position. Reads were subsequently checked for 
concordance with the expected barcode pattern ([AT][GC])x15, and counts of each barcode 
sequence were calculated in each sample separately. Tab delimited files containing barcode 
count information were used as input for the clustering algorithm starcode (Zorita, Cuscó, and 
Filion 2015) which was used to group together highly similar barcode sequences based on 
specific distance criteria. Specifically, starcode was run using parameters -s -d 1 -r 40 -i 
input_file -o output_file --print-clusters --seq-id. This lead to the generation of sequence groups 
(clusters) consisting of a consensus with frequency at least 40 times higher than any secondary 
sequence, and an edit distance equal to 1. These clusters were further modified using in-house 
python scripts, allowing only secondary sequences with a frequency <10 to be included in a 
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cluster. The calculation of barcode enrichment was performed using a combination of bash 
programming and in-house python scripts. Specifically, the average representation (% of 
frequency) of each barcode across all INITIAL samples was calculated first, considering each cell 
line separately. The cell line specific threshold to identify barcode enrichment was defined as 
the highest mean percentage observed in the INITIAL samples (MCF7: 0.001232; T47D:  
0.003869). Figures were generated in Rstudio v3.6.0 using the package ggplot2. 
 
3.2.6 Functional assays 
3.2.6.1 Analysis of cell proliferation by Hoechst staining 
Cell growth under different conditions (siRNA, treatment media) was analyzed with the 
molecular devices microscope IXM XLS. Cells were seeded in clear-bottomed 96 well black 
plates and they were transfected with siRNA or treated with treatment media. At different time 
points DNA was stained with fluorescent intercalating dye Hoechst-33258 (1:5000 dilution in 
growth media) for 45min. The plates were imaged and all nuclei within a certain size and 
intensity and were detected and counted by the Molecular Devices Software. For the cells 
transduced with the ClonTracer library that express RFP, the plates were scanned every day for 
7 days. All the cells showing red fluorescence with a pre-determined minimum intensity were 
detected and counted by the Molecular Devices Software. 
 
3.2.6.2 Cell Titer Glo Assay 
Cell titer Glo assay from Promega was used to assess cell viability through detection of ATP in 
cells as a measurement of their metabolic activity. The assay was performed according to 
manufacturer’s instructions. Briefly, the kit’s reagents were mixed and added to the wells of a 
96 well black plate. The incubation with the reagents resulted in the lysis of the cells which 
released ATP. The plate was placed on a shaker for 1 min to help the lysis. Luciferin, catalyzed in 
the assay by UtraGlo Luciferase, and the ATP generated oxyluciferin, which was detected via 
 
69 
 
luminescence measurement using the Glomax Explorer Plate Reader 10 minutes after 
incubation with the reagents.  
 
3.2.6.3 Transwell assays 
24 well plate format BioCoat Matrigel Invasion Chambers were thawed and 500 µl DMEM 
without FBS was added to pre-hydrate the matrix for 2 hours in the incubator at 37°C. After the 
rehydration the media was removed and 2x105 cells were seeded on the upper chamber in 200 
µl of media without FBS. As chemoattractant 500 µl DMEM supplemented with 20% FBS was 
used in the lower chamber. Invasion assays were stopped after 72 hours incubation at 37°C. 
Cells were swiped off the top off the upper chambers with a cotton swab and the lower 
chambers were by fixed with 4% PFA for 10 min. Transwell inserts were then moved to a new 
24 wells plate and stained with crystal violet for 40 min. After staining the inserts were washed 
in water to remove the staining in excess and let dry on the bench ON. For quantification the 
transwells were either eluted with 10% acetic acid and quantified with the Glomax Explorer 
Plate Reader measuring the absorbance at 590nm or imaged with the Zeiss LSM 800 
microscope. Images were exported and analyzed on Image J software using a macro built by Dr. 
Damir Krunic (Light Microscopy Core Facility, DKFZ). 
 
3.2.6.4 Analysis of apoptosis by AnnexinV/PI staining 
Apoptosis rate of cells in different conditions (siRNA, treatment media) was assessed with the 
Annexin/PI kit and analyzed with Flow Cytometry (FACS) according to manufacturer’s 
instructions. 2,5x104 cells were seeded in a 24 well plate and were transfected with siRNA or 
treated with treatment media. After 4 days the supernatant and the cells were collected in a 
96- deep well plate and centrifuged at 1200 rpm for 5 min. The supernatant was discarded and 
the pellet was washed once with 500 µl PBS. After discarding the washing buffer each sample 
was re-suspended in 100 µl of Annexin Binding Buffer (10x diluted with water) with 4 µl FITC 
Annexin V and 4 µl PI and incubated for 15 min at RT in the dark. After incubation the samples 
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were transferred to round-bottom tubes on ice and analyzed with the Flow Cytometer FACS 
Calibur. The cells were analyzed by gating on the physical parameters, forward scatter (FSC) and 
side scatter (SSC) and then selecting the positive cells based on the signal intensities in the FL1 
channel for Annexin V and FL2 channel for PI. Analysis was performed with FlowJo v10. 
 
3.2.6.5 Analysis of cell cycle by BrdU/7-AAD staining 
Cell cycle distribution of cells in different conditions (siRNA, treatment media) was assessed 
with Bromodeoxyuridin (BrdU) and 7-Aminoactinomycin D (7-AAD) staining and analyzed with 
FACS. 5x104 cells were seeded in a 12 well plate and were transfected with siRNA or treated 
with treatment media. After 4 days the cells were starved by changing the media to DMEM 
without FBS for 16 hours to synchronize the cell cycle distribution. After starvation the cells 
were incubated for 2 h with BrdU diluted to 10 µM in full growth media. Following the BrdU 
pulsing the cells were collected in a 96- deep well plate and centrifuged at 1200 rpm for 5 min. 
The supernatant was discarded and the pellets were washed and permeabilized with 700 µl 
Perm/Wash buffer (10x diluted with water). After centrifugation the supernatant was discarded 
and 250 µl Cytofix/Cytoperm buffer was added and incubated for 20 min at RT to fix the cells. 
The cells were washed as before and DNase was added and incubated for 1 hour at 37°C to 
expose the BrdU. After a new wash each sample was incubated with 10 µl FITC-anti BrdU 
antibody diluted in 50 µl PBS for 20 min at RT in the dark. Following the incubation, a new wash 
was performed and each sample was incubated with 4 µl 7-AAD diluted in 150 µl PBS. Cells 
were incubated 1hour in the dark, transferred to round-bottom tubes on ice and analyzed with 
the Flow Cytometer FACS Calibur. The cells were analyzed by gating on the physical parameters, 
forward scatter (FSC) and side scatter (SSC) and then gating the populations based on the signal 
intensities in the FL1 channel for BrdU and FL3 channel for 7-AAD. Analysis was performed with 
FlowJo v10. 
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3.2.7 In vivo experiments 
The mouse experiments were performed in the DKFZ animal facility by the group of Dr. Müller-
Decker under the animal experiment project number G272-16 using 4 weeks-old female NSG 
mice. All mice were injected with a 21-day release estrogen pellet (0.25 mg/pellet) in the neck 
under isoflurane anesthesia. After 7 days the mice were randomized and injected in the 
mammary fat pad (MFP) with 2.5 million cells (see Table 6 for the groups) in a 1:1 dilution with 
matrigel. 14 days after MFP injection the treatment pellets were injected in the neck under 
isoflurane anesthesia as reported in Table 6. Pellets were replaced every 60 days until mice 
were sacrificed. Mice were sacrificed when the tumor reached 1 cm of diameter in one of the 
dimensions, if they presented health problems or more than 20% weight loss or if they reached 
the planned end point of the experiment (120 days of treatment, 2 pellets). Due to health 
issues, one mouse from the Group 1 and one mouse from Group 2 were sacrificed and their 
results were excluded from further analysis. Additionally, in one mouse from Group 7 the tumor 
did not engraft and this mouse has been excluded from further analysis as well.  
Table 6: Conditions used for the in vivo experiment 
Group Number of 
mice 
Cell line 
Treatment 
pellet 
Pellet dosage (60 days 
release) 
1 6 MCF7- WT Estrogen 0,72 mg/pellet  
2 
6 
MCF7 ATF3 
KO1 
Estrogen 0,72 mg/pellet  
3 
6 
MCF7 ATF3 
KO2 
Estrogen 0,72 mg/pellet  
4 6 MCF7- WT tamoxifen 5 mg/pellet  
5 6 
MCF7 ATF3 
KO1 
tamoxifen 5 mg/pellet  
6 6 
MCF7 ATF3 
KO2 
tamoxifen 5 mg/pellet  
7 6 MCF7- WT letrozole 1,66 mg/pellet 
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8 6 
MCF7 ATF3 
KO1 
letrozole 1,66 mg/pellet 
9 6 
MCF7 ATF3 
KO2 
letrozole 1,66 mg/pellet 
 
3.2.8 Statistical Analysis and graphical illustration 
Unless otherwise mentioned, data are presented as mean of biological replicates ± SEM and 
statistical analyses were performed by unpaired two-tailed Student’s t-test using GraphPad 
Prism Software. p-values <0.05 were considered statistically significant and p-values <0.05, 
<0.01 and <0.001 are indicated with one, two and three asterisks, respectively. All graphs were 
generated using the GraphPad Prism Software, R or EaSeq and illustrated via Inkscape v 0.91 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
4. Results 
4.1. Part I: Time-resolved profiling of resistance development 
for identification of novel drivers 
4.1.1  Generation of resistant T47D cells 
To investigate in vitro the endocrine therapy resistance process I choose T47D, a luminal A cell 
line widely used as model of ER+ breast cancer. The generation of the resistant cell lines was 
done by cultivating two independent replicates of T47D for 1 year either with 100 nM 
tamoxifen (TAM) or in estrogen (E2) deprived media (Figure 5a). The resistance development 
process was performed in collaboration with another PhD student in the lab, Emre Sofyali. To 
assess the resistance development, cells were tested for their proliferative and invasive 
capabilities at different stages of the process. Cells treated with TAM showed increased viability 
as early as 5 months from the start of the treatment compared to sensitive cells (Figure 5b). 
This increased viability was not limited to the dose used to chronically treat the cells (100nM), 
but even to concentration 10 times higher. 
When comparing the proliferation rate of the cells under treatment, TAM treated cells were 
able to sustain a slow growth starting from month 5, even if slower that the parental cells 
(Figure 5c, left panel). Their proliferation speed continued to increase during the time of 
resistance development eventually matching with the one of the sensitive cells (Figure 5c, 
middle and right panel). In comparison, the cells deprived from estrogen remained in a non-
proliferative state for most of the resistance development, increasing their proliferative rate 
only after 1 year of chronic treatment (Figure 5c). Even so, these cells remained slower than 
their sensitive counterpart. 
Finally, as resistance phenotype is often associated with an increase in the invasive potential, 
the cells were tested in a transwell assay. Surprisingly, even though they were stuck in a non-
 
74 
 
proliferative state, the E2 deprived cells showed a significant increase in invasion compared the 
sensitive T47D (Figure 5d). However, no difference was observed for the TAM treated cells. 
This data collectively indicate that resistance to both TAM and E2 deprivation was successfully 
induced in these cells.  
 
Figure 6: Generation and characterization of resistance development in T47D  
(a) Schematic representation of resistance development during 1 year of treatment with 100nM 
TAM (T47D-T) or E2 deprivation (T47D-L). Three time points (5, 7 and 12 months) were chosen to 
investigate resistance development (b) Viability of cells treated for 72h with increasing doses of 
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TAM. Assay measurement performed with CellTiterGlo at indicated time points. (c) Proliferation 
assay measured as nuclei count at indicated time points. (d) 72h transwell invasion assay measured 
at indicated time points. All values are represented as relative values normalized to the control. For 
viability and nuclei count assays values are represented as mean + SD of 6 technical replicates, for 
invasion of 3 technical replicates. *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
 
4.1.2  Characterization of resistant MCF7 cells 
To be able to confirm the results obtained with the T47D cell line, we choose another luminal A 
cell line model, MCF7 and its resistant counterparts to TAM and E2 deprivation, which were 
kindly provided by Dr. Luca Magnani from Imperial College London (Nguyen et al. 2015). This 
cell line model has been developed as stated for T47D, with 1 year chronic treatment, therefore 
being a perfect control to generalize results in a second cell line (Figure 6a). However, these 
cells were available only at the endpoint of resistance induction, namely taken after 1 year of 
cultivation under selective pressure. 
 
Figure 7: Characterization of resistant MCF7  
(a) Schematic representation of resistance development performed in ICL for 1 year with 100nM 
TAM (MCF7-T) or E2 deprivation (MCF7-L). (b) Viability of cells treated for 72h with increasing 
doses of TAM. Assay measurement performed with CellTiterGlo. (c) Proliferation assay measured 
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as nuclei count at indicated time points. (d) 72h transwell invasion assay. All values are 
represented as relative values normalized to the control. Data are represented as mean + SEM. For 
viability and nuclei count assays n=2 (with 6 technical replicates), for invasion n=3 (with 3 
technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
 
To confirm their resistance phenotype the cells were tested for their viability under TAM 
treatment, proliferation and invasive capabilities. Indeed the MCF7-T showed increase viability 
under 100 and 500 nM TAM treatment compared to the sensitive MCF7 (Figure 6b). At the 
same time, all the cell lines had similar proliferative capabilities in their respective media 
(Figure 6c). Finally, cells were tested for their invasive potential in a transwell assay. In line with 
the results obtained with the T47D cell line system, MCF7-L showed a significantly increased 
invasion compared to MCF7 and MCF7-T (Figure 6d). 
The results obtained in the MCF7 cell line model thus confirm the phenotypes observed with 
resistant T47D and corroborate previously published data. 
 
4.1.3  Profiling of resistance development in T47D 
Several studies have investigated the differences between endocrine resistant and sensitive 
cells, but the understanding of the drivers of this phenomena remains limited. For this reason a 
time-resolved analysis of the early phases of resistance development is essential to identify 
genes responsible for this process. To address this I performed RNA-seq profiling of the cells 
during the resistance development at months 1, 2, 5 and 7. The RNA-seq results have been 
processed and analyzed by Maryam Soleimani and Perry Moerland (University of Amsterdam, 
UvA). Gene selected for downstream analysis were determined based on a set cut-off on the 
adjusted p-value on the changes in gene expression during time for each treatment 
independently. This selection resulted in 1477 genes for TAM treated and 1163 genes for E2 
deprived cells. To investigate genes’ behavior over time we utilized a clustering approach in 
order to group together genes with similar temporal expression patterns (Figure 8 a-b) 
(McDowell et al. 2018). The clusters were then investigated for enrichment of specific 
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pathways. An example is reported for Cluster 1 and 8 of the E2 deprived cells. Cluster 1, 
containing genes upregulated upon stress was enriched of MAPK signaling pathway, while 
cluster 8, containing genes downregulated upon stress, presented an enrichment for Cell cycle 
and DNA replications pathways (Table 7). This is in concordance with the behavior of the cells 
that are stuck in cell cycle progression, while activating MAPK pathways, responsible for several 
cellular processes, including survival. 
 
Figure 8: Unsupervised clustering of differentially expressed genes over time 
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(a) Clustering of 1477 differentially expressed genes in T47D under TAM treatment for 1, 2, 5 and 7 
months. (b) Clustering of 1163 differentially expressed genes in T47D under E2 deprivation for 1, 2, 
5 and 7 months. Genes were selected for clustering based on adjusted P-value cut-off for the ANOVA 
test: TAM: P<0.1, LTED: P<0.25. Plots represent gene expression over time, with each red line being 
a single gene and the blue line being the mean trend of the cluster. 
 
Table 7: KEGG pathway analysis on selected clusters in E2 deprived T47D 
KEGG Pathway KEGG id -E2 Cluster 1 p-value -E2 Cluster 8 p-value 
MAPK signaling pathway hsa04010 0.00182 0.324889 
Cell cycle hsa04110 0.79803 3.19E-28 
DNA replication hsa03030 1 6.83E-13 
 
The unsupervised clustering was not specific enough to serve as the basis for target selection, 
with most genes showing high fluctuations in comparison to the mean of the respective 
clusters. To investigate possible mediators of resistance I thus decided to focus on genes 
differentially expressed at early time points (1 and 2) and further narrowed down on genes that 
showed an upregulation compared to the non-treated cells (Figure 9 a). The selected gene lists 
included 786 and 761 genes for TAM treated and E2 deprived cells, respectively. To focus on 
the commonalities between the two treatments, only the 282 shared upregulated genes were 
selected for further analysis (Figure 9 b). Pathway analysis using KEGG pathway mapping on this 
gene list confirmed the results obtained from the cluster analysis, with a significant enrichment 
for the MAPK signaling pathway (Figure 9 c, red bars).  
A gene responsible for resistance development likely will not act independently, but be 
involved in the regulation of other genes. To identify transcriptional drivers responsible for the 
regulation of multiple genes in the list, I used the C3 MSigDB transcription factors (TFs) motif 
collection. Among several predicted TFs binding in the regulatory regions of those genes, only 
ATF3 was a member of the upregulated gene list itself, therefore being a suitable candidate for 
further investigations (Figure 9 a, c-blue bars). 
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Figure 9: Early upregulated genes in RNA-seq 
(a) Trend of the differentially expressed genes early upregulated at month 1 and 2 after treatment 
in T47D treated with TAM or E2 deprivation. ATF3 is highlighted in blue. (b) Venn diagram of the 
absolute number of genes differentially upregulated at month 1 and 2 after treatment. (c) Red: 
pathway enrichment analysis on the 282 common early upregulated genes using KEGG pathways 
mapping. Blue: predicted transcription factors binding analysis on the 282 common early 
upregulated genes using Molecular Signature Database C3 collection. The binding sites for 
ATF/ATF3 are highlighted in red.  
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Post-translational modifications of histone proteins are tightly associated with changes in gene 
expression. One of the most known and best studied modification is the acetylation of lysine 27 
of histone 3 (H3K27Ac) that has been associated with active promoters and enhancers 
(Creyghton et al. 2010). To investigate if the changes in gene expression were supported by a 
higher deposition of this permissive mark, I performed ChIP-seq using cells harvested at the 
same time points of the RNA-seq profiling. Data preprocessing and peak calling was performed 
by Giacomo Corleone (ICL). To focus the attention on the genes that were found differentially 
expressed at different time points, early upregulated genes from Figure 9 and downregulated 
genes in Cluster 8 of Figure 8 were used. The analysis was done for both treatments, and 
examples from the E2 deprived cells are shown here. Indeed a substantial increase in the 
H3k27Ac mark was detected around the transcription start site (TSS) of early upregulated genes 
1 month after the start of treatment. This increase was also present at later time points, 
however, mostly at lower levels (Figure 10 a). This indicates that the increase in gene 
expression detected at the RNA level is supported by a permissive chromatin structure that 
promotes TF binding and active transcription. On the other hand, downregulated genes showed 
a smaller H3K27Ac enrichment after 1 month, and a decrease in all consecutive time points. 
This supports the fact that these genes have reduced expression levels during resistance 
development. The difference between H3K27Ac profiles on early up and down genes is evident 
at all time points except before the treatment, where downregulated genes are having higher 
levels of the permissive mark (Figure 11 a). This is in agreement with the fact that gene Cluster 
8 contains mostly cell cycle related genes, which were probably highly expressed before 
treatment as cells were cycling. Indeed, after treatment administration, E2 deprived cells 
undergo a long non-proliferative phase (Figure 6 c) and recover only at late time points. To 
confirm this at single gene level, a representative gene for each cluster is shown. ATF3 was 
included in the list of early upregulated genes and predicted to regulate several genes in the 
list. Indeed the peaks at the two TSS of this gene are showing an enrichment at all time points, 
with the highest being month 1 (Figure 11 b). On the contrary E2F1, a master regulator of cell 
cycle included in Cluster 8 shows no changes in the H3K27Ac marks on the promoter region 
(Figure 11 c). 
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Figure 10: Heatmaps of the H3K27Ac profiles around TSS 
(a) ChIP-seq H3K27Ac profiles around the TSS of early upregulated genes (Figure 9) under E2 
deprivation. (b) ChIP-seq H3K27Ac profiles around the TSS of early downregulated genes (Cluster 
8) under E2 deprivation. Heatmaps represent ratio between each sample (T47D, -E2 1m, -E2 2m, -
E2 5m, -E2 7m) and the untreated sample (T47D). Green, blue and red indicate no change, decrease 
and increase in the acetylation levels respectively 
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Figure 11: H3K27Ac profiles around TSS of selected genes 
(a) Average H3K27Ac profiles around TSS of early up and downregulated genes under E2 
deprivation for 0, 1, 2, 5 and 7 months (b) H3K27Ac peaks at ATF3 gene locus under E2 deprivation 
for 0, 1, 2, 5 and 7 months. (b) H3K27Ac peaks at E2F1 gene locus under E2 deprivation for 0, 1, 2, 5 
and 7 months.   
 
Overall the Chip-seq data are in agreement with the RNA-seq data and confirm the target 
selection based on clustering and time-resolved trend of the genes. 
 
83 
 
To better understand the expression dynamics in the early response to the treatments, MCF7 
and T47D cells were treated for 2 weeks and selected genes were assessed with qRT-PCR. In 
both cell lines, ATF3 was increased after 1 week of treatment, with MCF7 showing also an early 
increase at 2 hours, probably corresponding to ATF3’s role as stress-response gene (Figure 12 a-
b). Genes involved in MAPK as RPS6KA5, ERBB2, TGFB2 and JUN, found upregulated in RNA-seq, 
showed a consistent increasing trend in early times as well in both the cell line models.  
 
Figure 12: Early upregulated genes under treatment 
(a) mRNA levels of early upregulated genes determined by qRT-PCR at different time points (2h, 6h, 
1d, 3d, 1w, 2w) during TAM treatment and E2 deprivation in MCF7. (b) mRNA levels of early 
upregulated genes determined by qRT-PCR at different time points (2h, 6h, 1d, 3d, 1w, 2w) during 
TAM treatment and E2 deprivation in T47D. All values are represented as relative values 
normalized to the untreated control (time 0). Data are shown as mean ± SEM, n=3 (each with 2 
technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
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At the same time, negative regulators of this pathway (BAMBI for TGFB2, DUSP1 and DUSP10 
for central kinases of MAPK pathway) showed an parallel increase, suggesting a feedback loop 
in the cells to try to shut down this processes (Figure 12 a-b). Notably, the increase of BAMBI in 
MCF7 LTED is limited, as expected from the minimal increase of TGFB2 in this cell line. 
These data indicate that the early upregulated genes detected in the RNA-seq screening are 
already increasing after 3-7 days of treatment in both cell lines.  
 
MAPK pathway is a known de-regulated pathway in endocrine resistance and was previously 
found to be affected early during therapy administration in the RNA-seq profiling (Peng et al. 
2017; Ghayad et al. 2010). To confirm that indeed the MAPK pathway was upregulated in the 
resistant cells at the proteomic level a targeted proteomic approach was used. Profiling of 
pathway activation was performed with Reverse Phase Protein Array (RPPA) using antibodies 
recognizing proteins involved in the MAPK pathway as well as the deepy interconnected 
PI3K/AKT pathway. To investigate not only the total protein levels, but also the activity of the 
selected pathways, antibodies recognizing specifically phosphorylated forms of the proteins 
were used. RPPA profiling revealed indeed an increase in the levels of many proteins involved in 
these pathways in both MCF7 and T47D resistant cells. In the two cell lines both proteins 
upstream of these pathway, as ERBB family members and RTK associated proteins like SOS and 
GAB1, and downstream effectors like MSKs, phospho-c-JUN and p-eIF4B showed a consistent 
increase across resistant cell lines. Of note also several central phosphorylated kinases, like 
AKT, MEK, RAF and p38 showed an augmented activity.  
These data therefore confirms the deregulation of the MAPK and PI3K-AKT pathways also at the 
protein level in the resistant model cell lines. 
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Figure 13: Heatmaps of RPPA-screened proteins in resistant cells 
Heatmaps of 35 total proteins and 18 phospho-proteins involved in MAPK and PI3K/AKT signaling 
pathways in MCF7 and T47D parental and resistant cells. Log2 normalized signal intensities for 
each protein are plotted and color-coding refers to relative intensities in each row and each cell line 
independently. 
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4.1.4  Validation of the role of ATF3 in resistance 
RNA-seq results identified ATF3 as an early-upregulated gene. Its annotated function as 
transcription factor and its role under stress conditions let me hypothesize that the encoded 
protein could also be important in the regulation of gene expression changes during resistance 
development (Hai and Hartman 2001; Hai et al. 1999). Indeed, during early phases of resistance 
development in T47D, ATF3 was found upregulated in both TAM treated and E2 deprived cells 
(Figure 14 a, Figure 12 a-b). qRT-PCR analysis of resistant T47D cells demonstrated that ATF3 
remained high also in resistant cells (Figure 14 c). Additionally, RNA-seq and qRT-PCR data 
confirmed that ATF3 was upregulated also in resistant MCF7, even if the levels were not as high 
in MCF7-L cells. (Figure 14 b, d). Finally, to check if the RNA levels were reflected also at the 
protein levels, all cell lines were investigated with WB. As ATF3 protein levels are low at 
baseline levels, anisomycin stimulation was used to induce its expression. Anisomycin is an 
antibiotic that inhibits DNA and protein synthesis, therefore inducing several stress pathways in 
the cells, including ATF3 expression (Lu, Chen, and Hai 2007; Hazzalin et al. 1998). Indeed, when 
stimulated with anisomycin, ATF3 became detectable in all the conditions and the resistant cells 
showed higher ATF3 protein expression compared to the parental cells in both cell lines (Figure 
14 e). 
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Figure 14: ATF3 expression levels are increased in resistant cell lines 
(a) Relative ATF3 mRNA levels determined by RNA-Seq in T47D at defined time points (1m, 2m, 
5m, 7m) during resistance development against TAM and E2. (b) Relative ATF3 mRNA levels 
determined by RNA-Seq in resistant MCF7 cell lines (c-d) Relative ATF3 mRNA levels determined 
by qRT-PCR in parental and resistant T47D and MCF7 SE. (e) ATF3 protein levels in parental and 
resistant MCF7 and T47D determined by WB after 2h anisomycin stimulation. β-actin levels are 
used as loading control. For RNA-Seq values are represented as relative Log2 Fold Change 
compared to parental cells. For qRT-PCR data are normalized to ACTB and then to parental cells and 
represented as mean + SEM, n=3 (each with 3 technical replicates). *** p-value <0.001, ** p-value 
<0.01, * p-value <0.05 
  
4.1.5 Knockdown of ATF3 affects cell number and apoptosis 
To establish a potential role of ATF3 in the resistance process I next performed an RNAi 
knockdown both in the parental and resistant cell lines. First, to decide if to use a specific siRNA 
or a pool, knockdown efficiency was evaluated both in MCF7 and T47D. The four siRNA tested 
showed a knockdown efficiency higher than 80% in MCF7 and slightly lower in T47D (Figure 15 
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a-b). To exclude possible off target effects of one of the siRNA, viability was assessed 7 days 
after transfection. All the siRNA showed a decrease in cell number of around 80% for MCF7 and 
of similar amplitude in T47D, even though with higher variance (Figure 15 c-d). As no siRNA 
showed low knockdown efficiency or any outlier effect on viability, I choose to use the siRNA 
pool to test the effect of the knockdown on the cells. Therefore from now on I will refer to the 
siRNA pool as siATF3. As resistant cells have higher levels of ATF3 compared to their sensitive 
counterpart the knockdown efficiency was tested for each cell line individually. Indeed ATF3 
was strongly downregulated both at the mRNA and protein level in all the tested cell lines 
(Figure 15 e-f). 
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Figure 15: RNAi  leads to efficient knockdown of ATF3 at RNA and protein levels 
(a-b) ATF3 mRNA levels determined by qRT-PCR 3 days after transfection with 4 single siRNA for 
ATF3 and the siATF3 pool. (c-d) Nuclei count measured with fluorescent microscopy 6 days after 
transfection with 4 single siRNA for ATF3 the siATF3 pool. (e) ATF3 mRNA levels determined by 
qRT-PCR 3 days after transfection with siCTRL and siATF3 pool. (f) ATF3 protein levels determined 
by WB 3 days after transfection with siCTRL and siATF3 pool and 2h stimulation with anisomycin. 
β-actin levels are used as loading control. For the qRT-PCR the values are normalized to ACTB levels 
and to the siCTRL. Data are represented as mean + SD of 3 technical replicates for the 
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deconvolution and as mean + SEM, n=3 (each with 3 technical replicates) for panel e. For the nuclei 
count the values are normalized to the seeding control and then to the siCTRL control. Data are 
represented as mean + SD of 5 technical replicates. *** p-value <0.001, ** p-value <0.01, * p-value 
<0.05 
 
Next, I tested if ATF3 knockdown was able to affect the levels of MAPK pathway-related genes. 
Indeed upon knockdown of ATF3, the expression of RPS6KA5 and ERBB2 was significantly 
decreased (Figure 16). Of note this decrease was only detected in resistant cells with elevated 
ATF3 expression, while the expression of the two genes did not change in wildtype cells. A 
known direct target of ATF3, DDIT3, was used as a positive control (Liu et al. 2012). Interestingly 
two downregulators of the MAPK pathway, DUSP10 and DUSP1, showed an opposite trend, as 
both were upregulated in the resistant cells upon ATF3 knockdown (Figure 16). This indicates 
that ATF3 might directly or indirectly affect downstream targets in different ways to induce and 
maintain the upregulation of MAPK signaling. 
 
Figure 16: Effect of ATF3 knockdown on upregulated genes 
mRNA levels of early upregulated genes determined by qRT-PCR in parental and resistant MCF7. 
Data are normalized to ACTB and then to parental cells and represented as mean + SEM, n=3 (each 
with 2 technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
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To test effect of ATF3 knockdown on cellular processes, cell viability was assessed 6 days after 
transfection, to allow the. ATF3 knockdown drastically affected the cell number both in the 
sensitive and resistant cells with a decrease of more than 50% in both MCF7 and T47D 
compared to the siCTRL transfected cells (Figure 17 a-d). The effect of siRNA was enhanced in 
both the parental cells treated with TAM or deprived from estrogen compared to the ones kept 
in E2 containing media, therefore increasing the sensitivity to the drug (Figure 17 a, c). These 
data show that ATF3 is essential for the cells both in normal condition and in the response to 
the drug and that its knockdown is highly toxic for the cells. 
 
Figure 17: Knockdown of ATF3 drastically affects cell viability 
(a-d) Nuclei count measured with fluorescent microscopy 6 days after transfection.  Parental cells 
were treated with the indicated media (+E2, +TAM, -E2) for the time of the assay. Resistant cells 
were kept in their respective media. All values are normalized to seeding control and then to the 
siCTRL control. Data are represented as mean + SEM, n=3 (each with 5 technical replicates). *** p-
value <0.001, ** p-value <0.01, * p-value <0.05 
 
To test if the observed decrease in cell number was accompanied by an increase in apoptosis, 
cells were analyzed after Annexin V/PI staining. Knockdown of ATF3 indeed induced a 
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significant increase in the percentage of both early and late apoptotic cells in MCF7-T, and only 
in late apoptotic cells apoptosis in MCF7-L (Figure 18 b, d). No significant difference was 
detected in the parental cells, even though an increase in the percentage of early apoptotic 
cells was evident in all the conditions(Figure 18 a, c). In parental T47D, ATF3 knockdown 
induced an increase in the early apoptotic cells fraction in presence of TAM or E2 deprivation, 
while no effect was detected in the untreated cells (Figure 18 e, g). This supports the 
importance of ATF3 in stress conditions. In resistant cells a significant increase in the 
percentage of both early and late apoptotic cells was evident in T47D-T. While there was no 
significant effect in the T47D-L, an increase in the percentages is evident in both the 
populations (Figure 18 f, h). 
Collectively, these results indicate a role of ATF3 in avoiding programmed cell death both in 
sensitive cells under endocrine stress (at least for T47D) and in the resistant cells. 
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Figure 18: Effect of ATF3 knockdown on apoptosis  
(a-h) Measurement of apoptosis rate 4 days after transfection with siCTRL and siATF3. Parental 
cells were treated with the indicated media (+E2, +TAM, -E2) for the time of the assay. Resistant 
cells were kept in their respective media. Plots represent the percentage of early and late apoptotic 
cells determined by Annexin V/PI staining. Data are represented as mean + SEM, n=2 (each with 3 
technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
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4.1.6 CRISPR-Cas9 knockout of ATF3 affects cell proliferation, cell cycle, 
apoptosis and invasion 
Since the transient knockdown of ATF3 with siRNA showed high toxicity, I decided to develop 
stable knockout cell lines to better investigate the role of ATF3 in resistance-related cellular 
processes. To exclude phenotypic effects related to off-target effects, 2 individual sgRNA 
targeting exon 3 of ATF3 gene were designed. Knockout was validated in clones derived from 
single cells using Sanger sequencing. Two selected clones, representing the two different 
sgRNAs, presented an insertion of 1 bp and a deletion of 17 bp, respectively (Figure 19 a). The 
Sanger sequencing results also confirmed purity of the clones, with editing efficacy higher than 
>98% (Figure 19 b). The sequencing identified these clones as homozygous biallelic knockouts, 
having the exact same mutation on both the alleles. The efficacy of the knockout was verified 
with WB and, given the low expression of ATF3 at the basal level, anisomycin was used to 
stimulate its expression. Indeed, after anisomycin stimulation, the WT cells showed a band for 
ATF3, while still no bands were detectable for the two knockout clones. 
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Figure 19: Crispr/Cas9 mediated knockout of ATF3 in MCF7 cells  
(a) Sanger sequencing visualization of the respective alterations in the ATF3 gene that have been 
induced by sgRNA-mediated CRISPR/Cas9 knockout, compared to the wildtype (WT) ATF3 gene 
sequence. Sequences of respective sgRNAs are underlined (above the WT sequence track) and PAM-
sequences (AGG) are indicated there with a red dotted line. (b) Percentage of indels contribution in 
the total population measured by Sanger sequencing. (c) Western blot validation of ATF3 knockout 
efficiency with or without 2h anisomycin stimulation. β-actin is used as loading control. 
 
To test the effect of ATF3 knockout on proliferation and viability, the cells were measured both 
in baseline and under treatment conditions. In presence of E2 the cells presented a similar 
proliferation rate, with KO1 showing a minimal but significant decrease in proliferation 
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compared to the WT, while KO2 showed the opposite trend (Figure 20 a). In presence of TAM 
and estrogen deprivation, however, the two ATF3 knockout clones displayed a significantly 
slower proliferation rate, with KO1 being the slowest (Figure 20 b, c). At the same time, the two 
knockout clones showed a significant reduction in the viability 8 days after estrogen 
deprivation. A similar reduction, even if smaller in size and significant only for KO1, was 
detected for the viability under TAM treatment (Figure 20 d). Altogether this data demonstrate 
that ATF3 plays a role in cellular response to treatment and that the lack of ATF3 increases the 
sensitivity of the cells to endocrine treatments. 
 
Figure 20: Effect of ATF3 knockout on proliferation and viability  
(a) Cell proliferation of MCF7 treated for 8 days with E2 and measured at indicated time points 
with nuclei count in fluorescent microscopy. (b) Cell proliferation of MCF7 treated for 8 days with 
TAM and measured at indicated time points with nuclei count in fluorescent microscopy. (c) Cell 
proliferation of MCF7 deprived for 8 days from E2 and measured at indicated time points with 
nuclei count in fluorescent microscopy. (d) Cell viability of MCF7 after 8 days of treatment with E2, 
TAM or without E2 measured with CellTiterGlo. All values for the proliferation assays are 
normalized to a seeding control. Values for the viability assay are normalized to the respective cell 
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treated with E2. Data are represented as mean ± SEM, n=3 (each with 5 technical replicates). *** p-
value <0.001, ** p-value <0.01, * p-value <0.05 
 
To understand if the effect of ATF3 knockout on proliferation and viability under treatment was 
mediated by changes in other relevant cellular process, the cells were next tested for their cell 
cycle distribution and apoptosis rate. While no differences in the cell cycle distribution were 
detected in baseline condition (+E2 in Figure 21 a), knockout clones showed a striking reduction 
in the percentage of cells entering S phase compared to their WT counterpart with both TAM 
and -E2 treatments (Figure 21 a). Interestingly, ATF3 knockout also affected the percentage of 
apoptotic cells under treatment. As before, no difference was observed in untreated condition 
with a similar number of early and late apoptotic cells. However, after TAM treatment and E2 
deprivation, both ATF3 KO clones showed a significant increase in the percentage of early 
apoptotic cells (Figure 21 b). Overall these results show that ATF3 knockout augments the 
sensitivity to endocrine therapy both by affecting cell cycle and increasing the apoptosis rate.  
 
Figure 21: Effect of ATF3 knockout on cell cycle and apoptosis  
(a) Cell cycle distribution of MCF7 treated for 4 days with E2, TAM or without E2. Plots represent 
the percentage of cells in the different cell cycle phases determined by BrdU/7AAD staining. 
Statistics performed on the S phases (yellow bars) (b) Measurement of apoptosis rate in MCF7 
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treated for 4 days with E2, TAM and without E2. Plots represent the percentage of early and late 
apoptotic cells determined by Annexin V/PI staining. Data are represented as mean + SEM, n=3 
(each with 3 technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
 
ATF3 has been implicated in the regulation of cellular invasion in several cancer entities (Jiang 
et al. 2016; Xuebing Li et al. 2017). To assess if the knockout induced altered invading 
capabilities cells were tested in a transwell matrigel assay. MCF7 are not highly invading cells, 
and in baseline conditions they have limited motility. Indeed without stimulation the cells 
showed low invading abilities even though KO2 displayed even less invading cells (Figure 22 a-
b). However, upon TFGβ1 stimulation, the WT cells showed the expected increase in invasion, 
while the two knockouts did not invade more than in the unstimulated condition (Figure 22 a-
b). These data suggest a potential role of ATF3 in TGF1-induced regulated invasion in breast 
cancer. 
 
 
Figure 22: Effect of ATF3 knockout on invasion  
(a) Representative microscopy images of transwell invasion assay through Matrigel. (b) 
Quantification of the number of invading cells. Values are expressed as relative to the unstimulated 
WT control. Data are represented as mean + SEM, n=3 (each with 2 technical replicates). *** p-value 
<0.001, ** p-value <0.01, * p-value <0.05 
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4.1.7 ATF3 overexpression induces resistance to endocrine therapy 
Since ATF3 knockout increased the sensitivity of WT MCF7 to TAM treatment and E2 
deprivation, I wanted to test if its overexpression could instead render these cells more 
resistant. For this reason stably overexpressing MCF7 and T47D were created by the DKFZ 
stable isogenic cell lines core facility. ATF3 overexpression was indeed evident at the mRNA 
level, with both overexpressing cell lines expressing high levels of ATF3 compared to cells 
infected with an empty vector (Figure 23 a-b). Accordingly, overexpression was detected also at 
the protein level in both cell lines (Figure 23 c). 
 
Figure 23: ATF3 overexpression in parental MCF7 and T47D  
(a-b) ATF3 mRNA levels determined by qRT-PCR in empty vector and ATF3 overexpressing MCF7 
and T47D cells. (c) Western blot validation of overexpression efficiency. Data are represented as 
mean + SEM, n=2 (each with 3 technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value 
<0.05 
 
To test the effect of ATF3 overexpression on proliferation and viability, the cells were measured 
both in baseline and under treatment conditions. In MCF7, while in presence of E2 the cells 
showed a similar proliferation rate, TAM treatment strongly affected growth in empty control 
cells while the ATF3 overexpressing cells proliferated significantly faster (Figure 24 a-b). The 
response to E2 deprivation, however, was not different between the two cell lines (Figure 24 c) 
suggesting that overexpression of ATF3 alone was not sufficient to explain the resistant 
phenotype. Indeed, viability measurements confirmed this difference, with ATF3 
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overexpressing cells showing a significantly increased viability under TAM treatment, while no 
difference was observed in E2 deprivation conditions (Figure 24 d). T47D cells overexpressing 
ATF3 instead displayed already higher proliferation than the empty control in presence of E2 
(Figure 24 e). However, the difference was increased when the cells were kept in presence of 
TAM or without E2, suggesting a more resistant phenotype of the ATF3 overexpressing cells 
(Figure 24 f-g). Viability measurements confirmed this trend, with the overexpressing cells 
showing significantly higher viability in presence of TAM as well as a not significant increase in 
E2 deprivation (Figure 24 h). 
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Figure 24: Effect of ATF3 overexpression on proliferation and viability  
(a) Cell proliferation of MCF7 treated for 8 days with E2 and measured at indicated time points 
with nuclei count in fluorescent microscopy. (b) Cell proliferation of MCF7 treated for 8 days with 
TAM and measured at indicated time points with nuclei count in fluorescent microscopy. (c) Cell 
proliferation of MCF7 deprived for 8 days from E2 and measured at indicated time points with 
nuclei count in fluorescent microscopy. (d) Cell viability of MCF7 after 8 days of treatment with E2, 
TAM or without E2 measured with CellTiterGlo. (e) Cell proliferation of T47D treated for 8 days 
with E2 and measured at indicated time points with nuclei count in fluorescent microscopy. (f) Cell 
proliferation of T47D treated for 8 days with TAM and measured at indicated time points with 
nuclei count in fluorescent microscopy. (g) Cell proliferation of T47D deprived for 8 days from E2 
and measured at indicated time points with nuclei count in fluorescent microscopy. (h) Cell 
viability of T47D after 8 days of treatment with E2, TAM or without E2 measured with CellTiterGlo. 
All values for the proliferation assays are normalized to a seeding control. Values for the viability 
assay are normalized to the respective cell treated with E2. Data are represented as mean ± SEM, 
n=3 (each with 5 technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
 
Next, I wanted to test the effect of ATF3 overexpression on cell cycle and apoptosis. In MCF7, 
when assessed in E2 containing media no difference was observed in the number of cells 
entering in S phase between the empty control and the overexpressing cells. Under TAM 
treatment and E2 deprivation, however, ATF3 overexpressing cells showed an increase in S 
phase, demonstrating less sensitivity to the treatments (Figure 25 a). Additionally, while no 
difference in the apoptosis rate was observed between the empty and the OE cells with or 
without E2, the percentage of early apoptotic cells that was induced upon TAM treatment was 
significantly lower in the ATF3 overexpressing cells (Figure 25 b). Similarly, in T47D no 
difference was observed in in the percentage of cycling cells between empty and 
overexpressing cells kept in E2 media. As in MCF7, ATF3 overexpression was able to prevent the 
cell cycle arrest induced my TAM, while no difference was observed under E2 deprivation 
(Figure 25 c). At the same time, the overexpression was able to significantly reduce also TAM-
induced early apoptosis compared to the empty control. A descrease in the early apoptotic 
cells, even if not statistically significant, was detected in E2 deprived overexpressing cells 
(Figure 25 d).  Overall these data demonstrate that ATF3 overexpression in able to induce 
resistance to TAM, in terms of higher proliferation and cell cycle and lower apoptosis rate 
under treatment, and in a lower extent to E2 deprivation, as reflected on the higher percentage 
of actively cycling cells in MCF7 and the higher proliferation rate in T47D. 
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Figure 25: Effect of ATF3 overexpression on cell cycle and apoptosis  
(a) Cell cycle distribution of MCF7 treated for 4 days with E2, TAM or without E2. (b) Measurement 
of apoptosis rate in MCF7 treated for 4 days with E2, TAM and without E2. (c) Cell cycle distribution 
of T47D treated for 4 days with E2, TAM or without E2. (d) Measurement of apoptosis rate in T47D 
treated for 4 days with E2, TAM and without E2. Cell cycle distribution plots represent the 
percentage of cells in the different cell cycle phases determined by BrdU/7AAD staining. Statistics 
performed on the S phases (yellow bars). Apoptosis plots represent the percentage of early and late 
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apoptotic cells determined by Annexin V/PI staining. Data are represented as mean + SEM, n=3 
(each with 3 technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
 
Since ATF3 knockout affected the invasion capabilities of MCF7, I decided to test if the 
overexpression was able to induce the opposite phenotype. While in unstimulated conditions 
ATF3 OE MCF7 cells displayed a similar number of invading cells as the empty control, upon 
stimulation the increase in invasion was enhanced in the overexpressing cells (Figure 26 a-b). 
Both T47D cell lines (empty control and ATF3 OE) were not able to invade through matrigel 
(data not shown). These data strengthen the indications obtained from the knockouts on the 
role of ATF3 in invasion and show similarities in the invasion capabilities of ATF3 overexpressing 
and resistant cells. 
 
Figure 26: Effect of ATF3 overexpression on invasion in MCF7  
(a) Representative microscopy images of transwell invasion assay through Matrigel. (b) 
Quantification of the number of invading cells. Values are expressed as relative to unstimulated 
empty control. Data are represented as mean + SEM, n=3 (each with 2 technical replicates). *** p-
value <0.001, ** p-value <0.01, * p-value <0.05 
 
4.1.8 ATF3 modulation affects downstream pathway activities 
RNA-seq revealed that during resistance development, the cells rewire their cellular processes, 
particularly affecting genes involved in MAPK pathway (Figure 9). Resistant cells were 
additionally proven to have higher activation of many phospho-proteins involved in this 
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pathway (Figure 13). To investigate if the knockout of ATF3 would directly affect the pathway 
activation profile of the cells under treatment I followed a targeted proteomic approach with 
the WT and the knockout clones after treatment either with TAM or E2 deprivation, using 
RPPA. The pathways chosen for investigation were MAPK for its role in upstream and 
downstream of ATF3, as well as PI3K/AKT due to its deep interconnection with MAPK and its 
previously demonstrated role in resistance (Figure 13) (Ma, Crowder, and Ellis 2011; Tokunaga 
et al. 2006)  
Acute treatment of WT MCF7 induced the upregulation of many proteins upstream of both the 
pathways, from tyrosin kinase receptors like ERBB family members to adjuvant proteins as SOS 
and GAB1, as well as downstream branches of effector kinases, like FAK, PAK1, and PAK2. Of 
note, also most of the investigated phospho-proteins revealed higher signals (Figure 27). In the 
PI3K/AKT pathway, several kinases as PDK1, AKT and PRAS40 showed a higher signal upon 
treatment, while consistently the phosphorylation of the downstram negative regulator of 
translation 4E-BP1 displayed a decrease. In parallel, MAPK pathwas showed increased activity 
by means of higher phosphorylation of p38, MEK1 and JNK, with only ERK1/2 showing 
decreased activity upon treatment (Figure 27).  
In the two knockouts, upon treatment administration, the pathway activation profile was 
drastically different. While some of the upregulated proteins in WT MCF7 upon TAM and E2 
deprivation treatment were not affected by the knockout (ERBB2/3, 4E-BP1, p42/44, Src), 
several other total and phospho-proteins did not show the same upregulation seen in the WT 
cells under treatment (Figure 27).  Notably, this was the case for most of the phospho proteins, 
including the phosphorylated forms of AKT, cRAF, MEK and eIF4B. On the other hand, phospho-
proteins that displayed downregulation upon treatmnent in the WT were upregulated in the 
knockouts, as pERK1/2 and p4E-BP1. These results indicate that ATF3 knockout indeed affects 
the regulation of several branches of the MAPK and PI3K/AKT pathways in response to the drug 
and the lack of ATF3 prevents the cells from augmenting the expression and activities of central 
proteins involved in these pathways.  
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As ATF3 overexpression induced the opposite phenotypic effects compared to the knockouts, 
i.e. increasing the resistance of sensitive cells to treatment, RPPA analysis was used to compare 
the ATF3 overexpression to the empty vector control. In MCF7, even though the effect on 
pathway alteration was not as strong as for the knockout, consistent changes in central proteins 
were detected. While upon TAM treatment a clear activation of these pathways was visible in 
the empty control, a stronger upregulation in the MAPK and PI3K/AKT pathways activation was 
detected in the overexpressing cells under E2 deprivation. Here, many phosphorylated protein 
such as LKB1, FAK and p38 showed an increase only in the E2 deprived ATF3 overexpressing 
cells (Figure 28 a). This finding was surprising as the phenotypic effect of the overexpression 
was stronger upon TAM treatment rather than in E2 deprivation (Figure 24, Figure 25). This 
could be mediated by specific proteins as pERK1 or peIF4B, which showed an upregulation upon 
both treatments in the overexpressing cells. However the fact that the MAPK and PI3K/AKT 
pathways are already highly induced in the empty vector control upon TAM treatment might 
mask further changes. In T47D the effect was less prominent, with some phospho-proteins 
being already upregulated in the treated empty control, particularly upon E2 deprivation 
(Figure 28 b). However, specific upregulation in the treated ATF3 overexpressing cells are 
visible, as phosphorylated p70 S6 kinase, FAK and PLCγ. This indicates that ATF3 overexpression 
might influence differently MCF7 and T47D in terms of downstream pathway activation. This 
could be mediated also by the background of somatic mutations present in these two cell lines 
as well as their different baseline levels of ATF3. 
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Figure 27: Heatmaps of RPPA-screened proteins in ATF3 knockout cells 
Heatmaps of 35 total proteins and 18 phospho-proteins involved in PI3K-AKT-MAPK signaling 
pathway in MCF7 WT and ATF3 KO clones. Log2 normalized signal intensities for each protein are 
plotted and color-coding refers to relative intensities in each row and each cell line independently. 
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Figure 28: Heatmaps of RPPA-screened proteins in ATF3 overexpressing cells 
(a-b) Heatmaps of 35 total proteins and 18 phospho-proteins involved in PI3K-AKT-MAPK 
signaling pathway in MCF7 and T47D Empty and ATF3 overexpressing (OE) cell lines. Log2 
normalized signal intensities for each protein are plotted and color-coding refers to relative 
intensities in each row and each cell line independently. 
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4.1.9 ATF3 stable knockdown does not re-sensitize resistant cells 
Modulation of ATF3 in sensitive cells affected their acute response to drugs, with the knockout 
increasing their sensitivity while overexpression conferred resistance. This demonstrates a role 
of ATF3 in drug response and resistance development. Then, I wanted to assess if the knockout 
of ATF3 was able to re-sensitize resistant cells. As the CRISPR approach requires single clone 
selection and a long drug holiday that might affect cellular behavior, I decided to use shRNAs 
knockdown, where antibiotic selection can be used to select transfected cells. Two different 
ATF3 shRNAs were used and a SCRAMBLE shRNA was transduced as a control. Knockdown of 
ATF3 was effective at the protein level in all the resistant cell lines, even though residual levels 
were still detected (Figure 29 a). However, as ATF3 levels are only 2 to 3 fold increased in 
resistant compared to the parental cells, this knockdown reduced ATF3 levels to the original 
baseline level (Figure 14).  
To assess the effect of ATF3 knockdown on treatment response, the cells were tested for their 
proliferative capabilities. Under TAM treatment, no difference was observed in the cell lines, 
with the two shATF3 and the shSCR showing the same proliferation rate (Figure 29 b, d). In the 
LTED cells, one of the T47D-L knockdowns showed a significantly slower proliferation, while the 
other shATF3 displayed the same proliferation as the shSCR (Figure 29 c). On the other hand, in 
MCF7-L shATF3_2 showed a higher proliferation rate, however in this cell the knockout had low 
efficiency (Figure 29 a, e). This data suggest that ATF3 knockdown is not able to re-sensitize 
already resistant cells to either TAM treatment and or E2 deprivation. 
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Figure 29: Effect of ATF3 stable knockdown on resistant cells' proliferation 
(a) Western blot validation of knockdown efficiency with two shRNA compared to a shSCR control 
(b-e) Cell proliferation of resistant MCF7 and T47D with nuclei count in fluorescent microscopy. All 
values for the proliferation assays are normalized to a seeding control. Data are represented as 
mean ± SEM, n=2 (each with 5 technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value 
<0.05 
 
To confirm these results I also tested the effect of the stable knockdown on cell cycle and 
apoptosis. Indeed no significant difference was detected in all the resistance cell lines regarding 
the number of cycling cells, apart from MCF7-T shATF3_2 which showed a reduction compared 
to the shSCR (Figure 30 a, b). At the same time, no difference was observed in the percentage 
of apoptotic cells, with only a decrease in the number of early apoptotic cells in T47D-T 
shATF3_1 cells (Figure 30 c, d). Overall these data are in agreement with the proliferation assay, 
showing no effect of the knockdown of ATF3 in resistant cells. 
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Figure 30: Effect of ATF3 stable knockdown on resistant cells' cell cycle and apoptosis  
(a-b) Cell cycle distribution of resistant MCF7 and T47D. Plots represents the percentage of cells in 
the different cell cycle phases determined by BrdU/7AAD staining (c-d) Measurement of apoptosis 
rate in resistant MCF7 and T47D. Plots represent the percentage of early and late apoptotic cells 
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determined by Annexin V/PI staining. Data are represented as mean + SEM, n=2 (each with 3 
technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
 
4.1.10 ATF3 regulates TGFB2 expression 
ATF3 was selected as a target based on its predicted role in regulating several genes 
upregulated in resistance. Indeed ATF3 knockout reduced the MAPK pathway activation upon 
treatment, confirming ATF3 as a putative regulator of this pathway. To understand if the ATF3 
effect on MAPK upregulation could be mediated by other proteins, I investigated the list of 
early upregulated genes for MAPK inducers. TGFβ2 was in the list of early upregulated genes 
and is a predicted ATF3 target. TGFB ligands are known inducers of the MAPK and PI3K/AKT 
signaling pathways in a SMAD-independent way, especially in cancer (Chapnick et al. 2011; 
Zhang 2009). While TGFβ1 has been deeply characterized as a mediator of resistance to 
endocrine therapies, TGFβ2 was reported to be upregulated under tamoxifen treatment, but its 
role in this context has not been investigated (Perry, Kang, and Greaves 1995; Yoo et al. 2008; 
Brandt et al. 2003). Still, the known role of TGFβ1 and the fact that both TGFβ1 and 2 act on the 
same receptor, make TGFβ2 a promising downstream target of ATF3. Therefore, together with 
Zuzana Koskova, a bachelor student I directly supervised, I decided to investigate the crosstalk 
between ATF3 and TGFβ2.  
TGFβ2 upregulation was detected in both resistant cell lines, with only MCF7-L not showing a 
difference in the RNA-seq data (Figure 31 a). TGFβ1, however, showed a decrease in early 
phases of resistance development in T47D, while no difference was visible in MCF7 (Figure 31 
c). This indicates a specific upregulation of TGFβ2 in these resistant models. qRT-PCR confirmed 
these results, showing strongly elevated levels of TGFβ2 IN MCF7-T and also a small increase in 
the MCF7-L (Figure 31 b). Finally, ELISA was used to test if the high levels seen in mRNA were 
actually translated in secreted protein by the cells. Indeed increased levels of TGFβ2 were 
detected in the supernatant of all resistant cells, apart from MCF7-L (Figure 31 d). 
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Figure 31: TGFβ2 levels in resistant cell lines 
(a-c) Relative TGFB1 and TGFB2 mRNA levels determined RNA-Seq in T47D at defined times (1m, 
2m, 5m, 7m) during resistance development against TAM and E2 and in MCF7 resistant to 100nM 
TAM (MCF7-T) and E2 deprivation (MCF7-L). (b) Relative ATF3 mRNA levels determined by qRT-
PCR in resistant T47D and MCF7. (d) ATF3 protein levels determined by ELISA in resistant T47D 
and MCF7. For RNA-Seq values are represented as relative Log2 Fold Change compared to parental 
cells. For qRT-PCR data are normalized to parental cells and represented as mean + SEM, n=3 (each 
with 3 technical replicates). For ELISA results are shown as total protein amount quantified via 
GloMax and represented as mean + SEM, n=3 (each with 2 technical replicates) *** p-value <0.001, 
** p-value <0.01, * p-value <0.05 
 
 
To test if ATF3 indeed regulates TGFβ2 expression, ATF3 was silenced in both MCF7 and T47D 
parental and resistant cells. Upon ATF3 knockdown TGFβ2 was reduced both at the mRNA and, 
to a lesser extent, at protein levels in all MCF7 cell lines (Figure 32 a-b). Surprisingly, however, 
ATF3 knockdown in T47D had the opposite effect, inducing an upregulation of TGFβ2 (Figure 32 
a-b). Since TGFβ1 has been proven to induce ATF3 expression, we also tested if TGFβ2 
expression might affect ATF3. While the silencing was effective both at the mRNA and protein 
levels, no difference in ATF3 expression was detected in any cell line (Figure 32 c-e).  
These results suggest a role of ATF3 in the regulation of TGFβ2, even though with completely 
distinct effects in MCF7 and T47D.  
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Figure 32: Effect of ATF3 knockdown on TGFB2 expression  
(a) Relative TGFB2 mRNA levels determined by qRT-PCR in siCTRL and siATF3 transfected cells. 
(b) Relative TGFB2 protein levels determined by ELISA in siCTRL and siATF3 transfected cells. (c-
d) Relative ATF3 and TGFB2 mRNA levels determined by qRT-PCR in siCTRL and siTGFB2 
transfected cells. (f) Relative TGFB2 protein levels determined by ELISA in siCTRL and siTGFB2 
transfected cells. mRNA values are normalized to siCTRL for each cell line. ELISA's values is 
normalized to RNA concentrations and then to siCTRL for each cell line. Data are represented as 
mean + SEM, n=3 (each with 3 technical replicates). *** p-value <0.001, ** p-value <0.01, * p-value 
<0.05 
 
Even though the knockdown of TGFβ2 did not affect the levels of ATF3, I tested if the 
stimulation with recombinant TGFβ2 could induce an upregulation in ATF3. In MCF7 TGFβ2 
stimulation increased ATF3 expression as a delayed response after 7 days, while no effect was 
seen in T47D (Figure 33 a). As a control for the stimulation BAMBI, a pseudo-receptor for TGFβ, 
was tested and was indeed upregulated in both cell lines (Figure 33 b). To test if TGFβ2 
stimulation was able to induce activation of the MAPK and PI3K/AKT pathways, the cells were 
tested with RPPA. As expected, upon stimulation, several total and phospho-proteins involved 
in the MAPK and PI3k/AKT cascades were found upregulated in both the cell lines, indicating 
the efficient activation of both pathways (Figure 33 c). 
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Overall these data connect ATF3 and TGFβ2 and indicate that they are able to induce each 
other as well as downstream MAPK signaling pathway activation. 
 
Figure 33: TGFβ2 stimulation affects ATF3 expression and PI3K-AKT-MAPK pathways 
activation  
(a) Relative ATF3 mRNA levels determined by qRT-PCR in MCF7 under TGFβ2 stimulation for the 
indicated times. (b) Relative BAMBI mRNA levels determined by qRT-PCR in MCF7 under TGFβ2 
stimulation for the indicated times. (c) Heatmaps of 35 total proteins and 18 phospho-proteins 
involved in PI3K-AKT-MAPK signaling pathway in MCF7 and stimulated with TGFβ2 for the 
indicated times. Log2 normalized signal intensities for each protein are plotted and color-coding 
refers to relative intensities in each row and each cell line independently. 
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4.1.11 ATF3 knockout effect on tumor growth in vivo 
ATF3 knockout had a striking effect on proliferation, cell cycle progression and apoptosis in 
vitro. To assess if this effect was reproducible in an in vivo xenograft model, mice were injected 
with the two ATF3KO clones and their WT counterpart and treated with E2, TAM or Letrozole 
(LET) pellets. In presence of E2 all the mice in the 3 groups had to be sacrificed due to tumor 
progression, with the 2 ATF3 knockouts reaching the ethical limit relatively slower than the WT 
(Figure 34 a, Table 8).  
 
Table 8: Percentage of and average time to sacrifice 
 + E2 + TAM + LET 
Percentage 
of mice 
sacrificed 
Average 
time to 
sacrifice 
Percentage 
of mice 
sacrificed 
Average 
time to 
sacrifice 
Percentage 
of mice 
sacrificed 
Average 
time to 
sacrifice 
WT 100% 64,4 33% 98,5 100% 65,8 
KO1 100% 97 0% NA 33% 106,5 
KO2 100% 81,6 33% 122,5 50% 102,3 
 
Under TAM treatment, similarly to what was seen in vitro, both the ATF3 knockouts showed 
slower proliferation. Astonishingly, all the mice injected with ATF3 KO1 displayed almost no 
growth when treated with TAM, with one mouse even showing complete remission (Figure 34 
b). Even if less drastic, a growth delay was detected also in the KO2 (Figure 34 c). Here 2 mice 
had to be sacrificed because of the tumor size, like in the WT, but much later (Table 8). 
Additionally, of the mice still alive at the end of the experiments, the WT ones presented the 
biggest tumors, with the two KO having significantly smaller masses (Figure 34 d). 
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In the WT group no decrease in proliferation was detected in the LET-treated mice compared to 
the E2-treated ones (Figure 35 a). This can be explained by the fact that we did not used 
ovariectomized mice and the levels of estrogen available might be enough for the WT cells to 
sustain a normal proliferation. Notably however, the two ATF3 KO clones presented a slower 
proliferation (Figure 35 b-c). Specifically, four and three mice from the KO1 and KO2 groups 
respectively, did not reached the size limit by the end of the experiment, having comparable 
sizes to the TAM treated groups. 
Altogether these data confirm the in vitro data and support the role of ATF3 in the regulation of 
resistance to endocrine therapy.  
 
Figure 34: Tumor growth of ATF3 knockdown in vivo under TAM treatment 
(a) Tumor volume in mice injected with MCF7 WT and treated with E2 or TAM for 120 days. (b) 
Tumor volume in mice injected with MCF7 ATF3KO1 and treated with E2 or TAM for 120 days. (c) 
Tumor volume in mice injected with MCF7 ATF3KO2 and treated with E2 or TAM for 120 days. (d) 
Tumor volume of mice still alive after 120 days of treatment. For tumor curves, each line represents 
a mice and each dot represents a measurement. For tumor volumes at the end, values are 
represented as mean ± SEM. *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
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Figure 35: Tumor growth of ATF3 knockdown in vivo under LET treatment 
(a) Tumor volume in mice injected with MCF7 WT and treated with E2 or LET for 120 days. (b) 
Tumor volume in mice injected with MCF7 ATF3KO1 and treated with E2 or LET for 120 days. (c) 
Tumor volume in mice injected with MCF7 ATF3KO2 and treated with E2 or LET for 120 days. (d) 
Each line represents a mice and each dot represents a measurement.  
 
 
4.1.12 ATF3 expression in patients datasets 
To evaluate the clinical relevance of the in vitro findings I decided to investigate ATF3 levels in 
publicly available datasets with gene expression data from patients treated with endocrine 
therapy. The GEO database contained 6 datasets suitable for analysis, having matched samples 
before and after therapy administration collected in different studies. Indeed, ATF3 was found 
significantly upregulated after therapy administration in 5 out of the 6 datasets (Figure 36 a-f). 
In all the datasets with more than one time point, ATF3 was mostly upregulated in the last (>90 
days of treatment), while only in the GSE80077 ATF3 was already upregulated after 14 days of 
treatment.  
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Figure 36: ATF3 expression in GEO datasets of patients treated with endocrine therapy  
(a) ATF3 expression in GSE80077 dataset, made of matched tumors before and 14 days after 
tamoxifen or letrozole administration. (b) ATF3 expression in in GSE10281 dataset, made of 
matched tumors before and 10 to 14 days after letrozole administration. (c) ATF3 expression in 
GSE20181 dataset, made of matched tumors before, 10-14 and 90 days after letrozole 
administration. (d) ATF3 expression in in GSE59515 dataset, made of matched tumors before, 10-
14 and 90 days after letrozole administration. (e) ATF3 expression in GSE55374 dataset, made of 
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matched tumors before, 10-14 and 90 days after letrozole administration. (d) ATF3 expression in in 
GSE111563 dataset, made of matched tumors before, in the first 120 days and after 120 days of 
letrozole administration. All values are represented as Log2 expression of the respective probe in 
individual patients ± SD. *** p-value <0.001, ** p-value <0.01, * p-value <0.05 
 
Strikingly, when analyzing the gene expression data from GSE111563 with the GEO2R function, 
ATF3 was found to be the top differentially expressed gene between the three time points 
(Table 9). Notably, many of the other top differentially expressed genes are predicted targets of 
ATF3, as well as upregulated genes in the early time points cell line model (EGR1, DUSP1, FOSB, 
JUN), corroborating the relevance of ATF3 in the regulation of the response to endocrine 
therapy. This finding suggested that a similar gene pattern was induced both in cell lines and 
patients biopsies. Indeed the early upregulated gene set (Figure 9) showed an enrichment in 
the treated samples compared to the pre-treatment biopsies in patients from GSE111563 
(Figure 37). This overlap is a strong confirmation of the relevance of the cell line model used as 
recapitulate effectively in vitro the in vivo gene expression profiles of treated tumors. 
 
Figure 37: Early upregulated genes in GSE111563  
Volcano plot of the early upregulated gene set (Figure 9) in the GSE111563 plotting the Log2 fold 
change between >120 days and pre-treatment time points. Red dots represent genes in the early 
upregulated gene set. 
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Overall these data confirm the increase in expression of ATF3 upon therapy administration and 
indicate the relevance of ATF3 in the clinical setting. 
 
Table 9: Top 10 differentially expressed probes  in GSE111563 
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4.2. Part II: Barcoding of luminal A cell lines reveals treatment 
and cell-line specific mechanisms of endocrine resistance 
development 
4.2.1 Barcoding of luminal A cell lines 
Resistance to endocrine therapy can be mediated by different genetic and epigenetic 
alterations. Even though different molecular pathways and cellular processes have been 
correlated to this process, the mechanisms underlying the initiation and selection of resistant 
cells is still unknown. To address this question, I used a cellular barcoding approach by 
employing the ClonTracer library (Bhang et al., 2015). This pooled barcode library, composed of 
more than 1 million unique barcodes, was used to tag MCF7 and T47D cells and track the clonal 
evolution of individual barcoded clones over the resistance development process (Figure 38). 
To do so, 100,000 cells were infected with the library with an extremely low MOI (0.05) to 
ensure the presence of a single barcode per each cell. The barcoded cells were then expanded 
to obtain sufficient cells to start the resistance development and to extract initial DNA as zero 
time point control. To be able to investigate the mechanisms of resistance, cells were cultivated 
for 8 months in presence of E2 as control, with 100nM TAM or without E2, each condition 
having five independent replicates. DNA from each replicate was then extracted, the barcodes 
were PCR amplified and sequenced (Figure 38). 
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Figure 38: Schematic representation of the barcoding experiment 
Scheme representing the steps used for the barcoding experiment: library transduction in MCF7 
and T47D cells, chronic treatment for 8 months to induce resistance development in 5 independent 
replicates for each condition (+E2, +TAM, -E2), PCR amplification of the barcodes and DNA 
sequencing. (Modified from HE Bhang et al. 2015) 
 
To assess the resistance development after 8 months of treatment, cells were tested in a 
proliferation assay over 7 days. For TAM treatment, the resistant cells treated with the drug 
showed significantly faster proliferation compared to the sensitive cells, even though they did 
not proliferate as fast as the untreated cells (Figure 39 a-b). To assess the estrogen deprivation 
effect in the sensitive clones, cell were pre-treated for 14 days as the proliferation arrest is 
delayed compared to TAM treatment. Indeed, sensitive cells showed almost no proliferation 
when deprived of E2, while resistant cells showed active proliferation, even if slower than the 
untreated sensitive cells (Figure 39 c-d). This data indicate that the treated clones in both cell 
lines had acquired resistance to both TAM and E2 deprivation after 8 months of chronic 
treatment. 
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Figure 39: Proliferation of barcoded MCF7 and T47D 
(a) Cell proliferation of barcoded MCF7 (treated for 6 days with E2 or TAM) and TAMR cells 
(treated with TAM) measured as RFP positive cells with fluorescent microscopy. (b) Cell 
proliferation of barcoded T47D (treated for 6 days with E2 or TAM) and TAMR cells (treated with 
TAM) measured as RFP positive cells with fluorescent microscopy. (c) Cell proliferation of barcoded 
MCF7 (treated with E2 for 6 days or deprived from E2 14d before the assay) and LTED cells 
(deprived form E2) measured as RFP positive cells with fluorescent microscopy. (d) Cell 
proliferation of barcoded T47D (treated with E2 for 6 days or deprived from E2 14d before the 
assay) and LTED cells (deprived form E2) measured as RFP positive cells with fluorescent 
microscopy. Each line represents the mean of 5 technical replicates for every independent clone.  
 
4.2.2 Sequencing of resistant clones reveals different drug selection 
mechanism 
Once the treated clones showed an increase in proliferation under treatment, indicating 
acquired resistance, the barcodes were sequenced to investigate the clonal dynamics. Five 
replicates of the initial DNA collected before the treatment administration were used as 
controls. The NGS data analysis was performed in collaboration with Dr. Luca Penso Dolfin 
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(Goncalves group, DKFZ). As expected, since all the samples were sequenced at the same 
sequencing depth, a similar number of reads was recovered from each of the individual 
replicate in both MCF7 and T47D (Figure 40 a-b). Since roughly 100,000 cells had been infected, 
the number of unique barcodes found in the initial population was as expected in MCF7, with 
110-115,000 barcodes in the five replicates. A lower number of different barcodes was 
sequenced in T47D, ranging between 35 and 45,000 individual barcodes in every replicate 
(Figure 40 c-d). As expected, all treated replicates showed a large decrease in the number of 
unique barcodes in both cell lines. However an unforeseen consistent reduction was present in 
the E2 treated clones as well, probably caused by selection of fast growing clones in plastic and 
loss of complexity during cell passaging (Figure 40 c-d). 
 
Figure 40: Number of reads and unique barcodes in barcoded cells 
(a) Absolute number of reads retrieved from sequencing of barcoded MCF7. (b) Absolute number of 
reads retrieved from sequencing of barcoded T47D. (c) Number of unique barcodes in barcoded 
T47D (d) Number of unique barcodes in barcoded T47D. Data represented as mean ± SD. Each dot 
represents an independent replicate 
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To assess the similarity between replicates, we checked the percentage of shared barcodes in 
the replicates having been treated in the same conditions. As expected, in the initial population 
a high number barcodes was shared, with >90% of the barcodes being in common between at 
least 2 replicates and around 50% shared between 4 or 5 replicates, in both MCF7 and T47D. In 
the replicates kept in presence of estrogens, the number of shared barcodes decreased, with 
around 50% being shared by at least 2 replicates. In the treated condition in both cell lines, this 
loss of shared barcodes was even higher, with only around 25% of the barcodes being shared by 
at least 2 replicates. When considering only the barcodes shared among all the replicates, the 
percentages drastically dropped to 1-5% in all the treated conditions. This suggests that the 
effect of the drug is likely not selecting specific clones but a stochastic enrichment of barcodes 
is taking place in each replicate. 
 
Figure 41: Percentage of shared barcodes between replicates  
Percentage of shared barcodes between the five replicates of the initial sample and each treatment 
group. Left panel represent MCF7, right panel represents T47D. 
 
 
Since the frequency of specific barcodes in the populations within replicates can have high 
variations and low frequency barcodes can influence the results, the number of enriched 
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barcodes compared to the initial population was calculated. A barcode was defined enriched if 
it was present in the sample in a frequency higher than the most frequent barcode detected in 
the initial samples. In MCF7 the replicates treated with E2 had around 100 enriched barcodes, 
on average slightly more than the TAMR clones, that presented with a higher variance. In 
contrast, the LTED replicates had only few enriched barcodes with one clone even having as 
little as 2 enriched barcodes (Figure 42 a). In T47D the number of enriched barcodes in the 
untreated replicates was around 20, while both resistant populations having not more than 10 
enriched barcodes (Figure 42 b). 
 
 
Figure 42: Number of enriched barcodes in barcoded cells 
(a) Number of enriched barcodes in the MCF7 clones. (b) Number of enriched barcodes in the T47D 
clones. Data represented as mean ± SEM. Each dot represents an independent replicate 
 
The enriched barcodes comprised most of the total cell population. In the control population 
(cells kept in presence of E2), few barcodes were enriched in all replicates of both cell line 
systems. This could be expected, as even without treatment some intrinsically more 
proliferative clones might take over the population over time. The selective pressure caused by 
endocrine treatments highly affects these numbers in different ways in the two cell lines and 
with the two distinct treatments. In MCF7 LTED all 5 replicates present different enriched 
barcodes, with only few shared between 2 replicates. This shows an apparent stochastic 
enrichment of barcodes in each replicate, with no selection of pre-resistant clones. Also in the 
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MCF7 TAMR replicates the vast majority of the enriched barcode were not shared, however 
there were indeed 25 barcodes, accounting for 10% of the total number of enriched barcodes, 
that were recurrent in 3 or 4 replicates indicating that these indeed had been selected under 
treatment pressure. In T47D both treatments presented enriched barcodes that were shared 
among all replicates. In T47D LTED only one barcode was shared, with the rest of the enriched 
barcodes being present only in 1 or 2 replicates. In T47D TAMR just 2 barcodes were highly 
enriched and recurrent in all replicates. An additional 4 barcodes were shared between 3 or 4 
replicates. These results suggest that in T47D a clear selection of pre-resistant clones had taken 
place. 
 
 
Figure 43: Number of enriched shared barcodes between replicates 
Number of enriched barcodes shared between the five replicates of and each treatment group. Left 
panel represent MCF7, right panel represents T47D. 
 
To investigate deeper the contribution of individual barcodes to the resistant pool and thus the 
mechanism of resistance development, we next investigated the frequency of the enriched 
barcodes and the commonalities between treatments. For a meaningful visualization, two 
different color coding regimes were applied: in MCF7 the top 5 barcodes of each resistant 
replicate were color-coded, while in T47D the top 25 enriched barcodes in the resistant clones 
overall.  
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In MCF7 TAMR several barcodes contributed to the final pool. To our surprise, the top enriched 
barcodes of each replicate were different compared to the other replicates, indicating that 
different clones were selected. However no barcode presented a high enrichment and all the 
enriched barcodes contributed in small percentage to the pool.  
As expected from the number of enriched barcodes from Figure 42, in MCF7 LTED the situation 
was completely different. Here few barcodes contributed to the vast majority of the pool, with 
replicate 5 being almost completely derived from a single cell. All the enriched barcodes were 
different among the replicates, confirming the stochasticity of the selection process.  
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Figure 44: Individual barcodes sharing among treatments and replicates 
(a) Frequency of individual barcodes in each replicate of MCF7. (b) Frequency of individual barcodes in 
each replicate of T47D. In MCF7 the top 5 barcodes for each replicate in the TAMR and LTED conditions 
are differentially color-coded. In T47D the overall top 25 barcodes in the TAMR and LTED conditions are 
differentially color-coded. 
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Interestingly, in T47D TAMR four replicates were composed mostly of two barcodes, while the 
TAMR_5 had higher enrichment of 2 other barcodes. This replicate however presented also the 
same 2 shared barcodes of the other replicates but in much lower frequencies. Notably, also 
lowly enriched barcodes were shared among 3 or 4 replicates. This data indicates that in T47D 
TAMR a selection of pre-resistant clones took place as the barcodes are shared among 
replicates.  
Finally, T47D LTED displayed an even different scenario. All of the replicates shared one 
barcode that contributed differently to the pool proportion (from 50% in replicate 1 to 1% in 
replicate 2). This barcodes was however enriched also in the E2 treated cells therefore having a 
proliferating advantage over other clones that was thus not only related to resistance. The 
other highly enriched barcodes were different in each replicates, with the exception of the 
violet one, that was shared between clone 1 and 4. As in the MCF7 LTED, one of the replicates 
was almost completely derived from a single clone. These data indicate that in T47D LTED there 
is both stochastic selection and enrichment of pre-resistant clones. 
Overall the analysis of shared barcodes among replicates and their enrichment revealed 
different mechanisms of resistance development. Each cell line and each treatment displayed a 
unique clonal profile that remark the complexity of the clonal selection in the resistance 
process. 
As the enrichment of the same two barcodes in T47D TAMR replicates hinted to a specific 
selection of clones, I decided to rule out the possibility that this selection was driven by the viral 
integration and consequent disruprion of a specific gene locus. To address this, we applied S-
EPTS/LM-PCR, performed by Genewerk (Schmidt et al. 2001) using one of the T47D TAMR 
samples (3), one control (+E2_2) and the T47D LTED_2, that was characterized by a dominant 
clone.  The analysis of T47D TAMR_3 identified two insertion sites in chromosomes 6 and 8, 
with a frequency of 0.58 and 0.34 respectively (Table 10). These frequencies are in contrast 
with the results from the barcode DNA seq and indicate that the two barcodes integrated in 
distinct cells. Additionally, the insertion loci are not mapping to coding or regulatory regions 
therefore making the viral integration sites the driving cause of selection highly unlikely. The 
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analysis of T47D LTED_2 revealed that the dominant clone had the barcode integrated in 
chromosome 4 (Table 10). Also in this case, the insertion site was several kilobases away from 
any coding region or regulatory element. 
These data indicate that the viral integration sites did not disrupt any known coding or 
regulatory region, therefore allowing us to exclude this as a driving force in the clonal selection. 
Table 10: Integration site analysis 
Integration site T47D TAMR_3 Freq. T47D LTED_2 Freq. T47D +E2_2 Freq. 
Chr 6: 120,131,260 0.579 NA 0.000164 
Chr 8: 66,103,520 0.342 NA NA 
Chr 4: 112,000,728 NA 0.999 0.000937 
 
 
4.2.3 Pathway activation profiling of individual replicates 
Since the replicates inside a treatment group had different enriched barcodes and were thus 
derived in most cases from different cells of origin, I wanted to investigate if they had acquired 
different alterations in pathway activities during the resistance development process. To 
address this and to identify the differences between replicates and treatments at the functional 
level, I used RPPA to screen pathways known to be involved in resistance development, as 
WNT, MAPK and PI3K/AKT. WNT pathway was characterized by probing 12 proteins. The 
screening of MCF7 cells revealed an upregulation of WNT pathways in all the TAMR replicates, 
characterized by the high expression of total and phospho β-catenin, CSNK1E, DKK1 and 
CSNK2B, and the low expression of the negative regulator CTNNBIP1 (Figure 45 a). MCF7 LTED 
cells, instead, displayed different profiles, with LTED_5 having high upregulation in all the 
proteins in the WNT pathway, LTED_ 1 and LTED_4 with a partial upregulation, and LTED_2 and 
LTED_3 showing a downregulation, with low levels of most of the proteins and high levels of 
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the negative regulator CTNNBIP1 (Figure 45 a). T47D resistant cells showed a lower WNT 
pathway activity of resistant cells compared to MCF7. Also in T47D, TAMR replicates showed 
similar profiles, while LTED had higher differences. Of note, LTED_2 showed a distinct profile, 
with upregulation of activators of the WNT pathway and downregulation of CTNNBIP1 (Figure 
45 b). 
Another pathway screened was PI3K/AKT/mTOR pathway. While this pathway was not active in 
MCF7 treated with E2, as indicated by high levels of the negative regulator PTEN, all the TAMR 
replicates showed activation of the pathway, with upregulation of phosphorylated S6, p90RSK, 
4E-BP1, p70, NF-kB and EIF4B. Additionally, TAMR_3 and 4 also presented a specific 
upregulation of the PRAS40 branch of the AKT pathway (Figure 45 c). Also in this pathway LTED 
cells showed distinct profiles. Replicate 5 displayed an over-activation of the PI3K/AKT/mTOR 
pathway with most of the proteins showing high intensities and a parallel inactivation of PTEN. 
LTED_3 and 4 had no activation in most of the proteins and high levels of the negative regulator 
PTEN, while LTED_1 and 2 showed intermediate profiles (Figure 45 c). As several clones 
contribute to these replicates, this intermediate profile could indicate that the individual clones 
might have different pathway activation profiles. In T47D, E2 treated cells showed a more 
active PI3K/AKT/mTOR pathway as baseline, but specific changes were detected in the 
replicates of resistant cells. Of note, the only phospho-protein consistently upregulated the 
resistant replicates was pPDK1, however downstream effector proteins showed mixed profiles. 
While in TAM the PI3K/AKT/mTOR pathway was at similar levels compared to the E2 treated 
cells (or higher for specific branches like PRAS40), LTED replicates displayed a general 
downregulation, apart from the levels of pAKT. Interestingly LTED_2 showed high levels of total 
and phospho 4E-BP1, showing a potential dependency on this branch of the AKT pathway 
(Figure 45 d). 
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Figure 45: Heatmaps of RPPA-screened pathways  
(a-b) Heatmaps of 12 proteins and phospho-proteins involved in WNT signaling pathway in MCF7 
and T47D. (c-d) Heatmaps of 21 proteins and phospho-proteins involved in PI3K/AKT signaling 
pathway in MCF7 and T47D. (e-f) Heatmaps of 19 proteins and phospho-proteins involved in MAPK 
signaling pathway in MCF7 and T47D. Log2 normalized signal intensities for each protein are 
plotted and color-coding refers to relative intensities in each row independently. Proteins are 
ordered by hierarchical clustering. 
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Finally, MAPK pathway analysis revealed an overall upregulation in all replicates of MCF7 TAMR 
as depicted by high intensities of central kinases (Figure 45 e). As before, in MCF7 LTED cells 
replicate number 5 (mostly derived from a single cell of origin), showed an upregulation of the 
pathway, suggesting that this replicate has redundant mechanisms for promoting resistant 
features. LTED_4 displayed partial upregulation while the other 3 replicates had low levels of 
most of the proteins in the pathway. Notably, however, LTED_1 showed specific upregulation of 
PLCγ, indicating a possible peculiar mechanism of resistance in at least one of the 6 highly 
enriched clones in this replicate (Figure 45 e). T47D, instead, presented a general 
downregulation of the MAPK pathway, yet with focal upregulation in central kinases. Examples 
are upregulation of pMEK and ERK in TAMR_2 and LTED_1 or pMEK, pSRC and pJNK in TAMR_3 
and 4. While LTED showed a downregulation of MAPK pathway overall, LTED_2 seems to still 
have higher activities compared to the other replicates as indicated by the high intensities of 
many phospho-proteins. 
Overall the RPPA screening revealed general treatment-specific changes in the resistant 
replicates as well as replicate-specific ones that might indicate different mechanisms of 
resistance. The differences in pathway activation are frequently reflecting distinct barcode 
compositions as for MCF7_LTED5 and T47D_LTED2 (Figure 44) that support the theory of 
independent mechanisms of resistance development based on the clonal selection.  
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5. Discussion 
Resistance to endocrine therapy in breast cancer is an urgent clinical problem that affects 
around 40% of the luminal patients. Recent developments allowed the use of new second line 
treatments that helped improving the prognosis, but the mortality rate for relapsing patients 
remains extremely high. The limited understanding of the mechanisms underlying resistance 
development requires greater efforts to identify new targetable genes and pathways involved 
in the process. In this view, I aimed to identify novel targets through a longitudinal screening 
during the development of endocrine resistance in ER positive cell lines. This led to the 
identification of ATF3 as a driver of the resistance process, being involved in the rewiring of 
MAPK pathway. This study indeed shows that interfering with this gene can increase the 
sensitivity to endocrine therapies and re-sensitize resistant cells. In addition, in this thesis I also 
addressed the role of clonality in the resistance process using a barcoding technique. This 
approach revealed that the resistance mechanism is complex and one general rule cannot be 
applied to all patients and treatments.  
 
5.1. Longitudinal profiling reveals ATF3 as a potential 
mediator of resistance 
Studies that aim to recapitulate in vitro the resistance development commonly focus on 
resistant cell line models and compare these to their sensitive counterpart. This approach has 
revealed numerous key alterations involved in resistance development and has led to the 
development of new therapeutic approaches. However there is a lack of knowledge regarding 
genes responsible for the survival of the cells to the acute cytotoxic effect of the drugs and the 
rewiring of their molecular features. From a therapeutic perspective, it is essential to 
understand the drivers of the resistance phenomena, rather than the downstream alterations, 
to be able to propose new first-line targets that can help delay the resistance development or 
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prevent it at all. In this view a deep understanding of the early phases of the treatment may 
help pinpoint causes and effects, and how they are connected. This approach indeed identified 
a novel candidate, ATF3, as a central player in this process. Activating Transcription Factor 3 
(ATF3) is a transcription factor of the ATF/cAMP responsive element binding (CREB) family and 
is involved in several cellular responses. ATF3 is expressed at low levels in baseline conditions, 
but has been shown to be rapidly induced by stress signals to alter several cellular processes 
relevant to cancer progression (Hai et al. 1999; Gokulnath, Partridge, and Selvamurugan 2015; 
Ameri et al. 2007). Two different isoforms of ATF3 have been reported in the literature. The 
long and most abundant isoform, commonly referred to as ATF3, has been shown to homo- or 
hetero-dimerize with other proteins, as reported in Table 11.  
 
Table 11: Binding partners of ATF3 and dimers' role in physiology 
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The role of ATF3 in the regulation of transcriptional activity depends on the binding partner and 
the promoter context. As an example, binding of ATF3 to JUN or JUND usually represses 
transcription, while its dimerization with JUNB can have both active and repressive roles 
(Thompson, Xu, and Williams 2009). The shorter isoform (ATF3ΔZip) has been reported to not 
bind to DNA, therefore suggested to mostly act by sequestration of co-factors and subsequent 
stimulation of transcriptional activity (B. P. Chen et al. 1994; Hashimoto et al. 2002). 
Due to its potential dual role, ATF3 has been found to have different effects on cancer 
progression. In prostate cancer ATF3 expression has been correlated with worst prognosis and 
its overexpression has been associated with increased proliferation and metastasis formation 
(Pelzer et al. 2006). Similarly, ATF3 was reported to promote cell invasion and contribute to 
tumor spreading in colon cancer (Ishiguro et al. 2000). Additionally, ATF3 knockdown has been 
proved to impairs Hodgkin Lymphoma as well as glioblastoma and lung cancer cells growth and 
viability (Janz et al. 2006; MA et al. 2015; Xuebing Li et al. 2017). On the other hand, several 
studies reported and oncosuppressive roles of ATF3. Its overexpression in liver cancer and 
hepatocellular carcinoma cells reduced proliferation and motility, while increasing induced 
apoptosis (Chen et al., 2018; Li et al., 2018). Other reports showed ATF3 as inhibitor of invasion 
and migration both in colorectal cancer and ovarian cancer cells (Inoue et al. 2018; Bottone 
2005; Syed et al. 2005). It thus seems that the role of ATF3 in cancer progression is highly 
context dependent and tumor-type specific. 
In breast cancer ATF3 has been mostly characterized as an oncogene. The ATF3 gene maps to 
chromosome 1q32.3 in the q1 amplicon. The q1 amplicon is amplified in around 53% of all 
breast cancers being the most amplified region in breast cancer (Middleton et al. 2018). 
Overexpression of ATF3 was able to induce spontaneous lesion in the mammary glands via 
upregulation of the WNT/β-catenin pathway and to promote cancer-initiating features in 
immortalized mammary epithelial MCF10A cells via the TGFβ pathway (Wang et al. 2008; Yan et 
al. 2011; Yin et al. 2010). Additionally higher expression of ATF3 has been correlated with worst 
overall survival in breast cancer (Cao, Yang, and Jiang 2013). ATF3 has been investigated also in 
the context of chemotherapy and radiotherapy, with surprisingly opposite roles. While being 
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upregulated upon both treatments, in chemotherapy it has been described as a mediator of 
cytotoxicity, whereas regulating resistance to treatment with radiotherapy (W. Zhao et al. 2018; 
Hasim et al. 2018). 
Considering this, it was not surprising to find ATF3 among the upregulated genes in response to 
endocrine therapy treatment. Of particular relevance was the fact that ATF3 was not just 
increased in the resistance cells, but throughout the process of resistance development as well. 
Indeed the time-resolved profiling allowed us to discriminate between gene clusters with 
different behaviors during the resistance process. Notably ATF3 was also a predicted regulator 
of several genes that shared with ATF3 the peculiar profile of being upregulated after short-
time therapy administration. Several of these genes have been reported to be induced by 
endocrine therapy administration and resistance, as SOX2, DUSP10 and TGFB2 (Hrstka et al. 
2016; Piva et al. 2014; Brandt et al. 2003). Another striking example is the AP-1 complex which 
is well characterized as a mediator of endocrine resistance development (Malorni et al. 2016; 
He et al. 2018). Indeed both immediate early stress-response genes FOS and JUN were 
upregulated early in my TAMR and LTED systems. The encoded proteins are not only binding 
partners of ATF3, but are also ATF3 target genes, as predicted by TF binding site analysis based 
on the MSigDB database. Additionally, it has been shown by ChIP-seq that ATF3 not only 
localizes to ATF3 TF/CRE motifs (5’-TGACGTCA-3’) but also the AP-1 sequence (5’-TGASTCA-3’, 
S = C/G) therefore indicating that that AP-1 and ATF3 could act together in promoting resistance 
development (J. Zhao et al. 2016). 
 
5.2. ATF3 mediates resistance to therapy through regulation of 
the MAPK signaling pathway 
The findings that ATF3 was upregulated upon treatment stress and might mediate the 
expression of several other genes involved in the MAPK pathway let to the hypothesis that this 
gene is a central player in resistance development. To test this I applied different approaches to 
modulate ATF3 expression as siRNA induced RNA interference, shRNA downregulation, 
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CRISPR/Cas9 knockout, and lentiviral overexpression. Indeed ATF3 knockdown with siRNA 
highly affected cell viability and proliferation in MCF7 and T47D, but the effect was not limited 
to the treated condition. The physiological role of ATF3 varies in different cells, but it is a 
central protein in the regulation of the stress caused by DNA-damage repair and cell cycle 
progression (Rohini, Haritha Menon, and Selvamurugan 2018). Additionally upon environmental 
stress, ATF3 expression increases to mediate the transcription of downstream genes and allow 
the cell to cope with harming stimuli. This could be the reason of the high toxicity of the RNAi 
approach, in which the stress caused by the method itself and the knockdown of ATF3 can 
cooperate towards the fatal phenotype detected.  
Due to the difficulty to interpret RNAi results I moved to a stable knockout approach using 
CRISPR/Cas9. CRISPR/Cas9-induced double strand breaks can be repaired by non-homologous 
end joining (NHEJ) or by homology directed repair (HDR) if a template is present (Mao et al. 
2008; Ran et al. 2013). While NHEJ is the preferred method for non-dividing cells, after one of 
the allele is repaired with this method, this could be used as a template for the HDR if Cas9 is 
still present and actively cutting while the cells divide. This mechanism allows obtaining 
homozygous mutations and indeed single-clone-derived homozygous biallelic ATF3 knockout, 
carrying the same mutation in both the alleles, were successfully obtained from MCF7. In 
contrast, no viable knockout clones were retrieved from T47D even after several attempts 
performed by me as well as by a collaborator at the Weizmann Institute of Science. T47D 
express higher levels of ATF3 compared to MCF7 cell line (The Human Protein Atlas) and might 
be dependent on this transcription factor for survival. Therefore, I decided to proceed with the 
validation of the role of ATF3 kncokout using MCF7. While the ATF3 knockout clones had similar 
proliferation, cell cycle and apoptotic rate compared to the WT in normal growth conditions, 
under stress all these processes were drastically affected. Indeed ATF3 knockout caused a 
strong decrease in proliferation as well as in the number of actively cycling cells under TAM and 
E2 deprivation, thus increasing the phenotypic effects of treatments in the cells. At the same 
time the apoptosis rate increased, further supporting the role of ATF3 in regulating stress 
response. These results are in line with recently published data on the role ATF3 in 
radioresistance in MCF cells, therefore reinforcing the understanding of ATF3 in treatment 
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response in breast cancer (W. Zhao et al. 2018). Additionally ATF3 knockout was able to reduce 
aggressive features, like invasion, commonly associated to the resistant phenotype. 
Next I tested if the overexpression of ATF3 could induce the opposite effect and confer 
resistance to endocrine therapy. Indeed high levels of ATF3 were able to reduce the cytotoxic 
effects of TAM and, to a lesser extent, also of E2 deprivation in terms of proliferation, cell cycle 
progression and apoptosis rate. Moreover ATF3 overexpression induced a more invasive 
phenotype upon TGFβ1 stimulation in MCF7, suggesting a putative role of ATF3 in the 
metastatic spreading. 
ATF3 has been described as a downstream effector of the MAPK pathway through several 
distinct branches and mechanisms in different contexts. First, ATF3 promoter has been shown 
to be activated by the binding of ATF2 and c-jun, two downstream effectors of MAPK signaling 
(Liang et al. 1996). ATF3 upregulation under stress was proven to be mediated exclusively by 
the p38 signaling pathway in HeLa cells, while through ERK, SAPK and p38 in colorectal cancer 
(Lu, Chen, and Hai 2007; Hackl et al. 2010). Other reports showed that its activation is mediated 
through ERK and p38α in myocytes or by ERK/JNK but not by p38 in rat brains (Guo et al. 2015; 
Koivisto et al. 2014). Again, these findings demonstrate that the regulation of ATF3 is highly cell 
and context specific. In breast cancer and particularly in resistance to treatments, ATF3 
expression has been described as mediated by pAKT in radioresistance, while mostly by JNK 
pathway in chemoresistance (Hasim et al. 2018; W. Zhao et al. 2018). Therefore, while the 
mechanisms of ATF3 induction through MAPK and AKT have been extensively described, the 
downstream activity of ATF3 to propagate the signal is not well studied. 
 As RNA-seq results provided insights into the regulation of downstream effectors of MAPK 
signaling pathway by ATF3, I further explored this through a phospho-proteomic screening with 
RPPA. This approach revealed a drastic difference in pathway activation profiles in WT cells and 
ATF3 knockout cells. While in the WT cells endocrine treatments induced activation in several 
central phospho-proteins as AKT, p38, MEK1, PDK1 and JNK, as well as downstream effectors 
like phospho c-jun and eIF4B, the two knockout clones displayed a generally less active MAPK 
and PI3K/AKT pathways. This indicates a central role of ATF3 in regulating MAPK and PI3K/AKT 
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signaling pathways under therapy and that the lack of ATF3 prevents activation of these 
pathways as well as of resistance processes. Even if in lower intensity, ATF3 overexpression 
adjuvated activation of these pathways in both MCF7 and T47D, corroborating the phenotypic 
findings that ATF3 overexpression confers resistance in sensitive cells. 
Stable knockdown of ATF3 was also tested in resistant cells, using an shRNA approach to 
downregulate ATF3 expression. This was used because lentiviral delivery of shRNA allows for a 
rapid selection with antibiotics of resistant cells that carry the shRNA, while a CRISPR/Cas9 
approach requires single clone selection and expansion. This would select for clones that 
eventually adapted to survive without ATF3 in the presence of the drug, therefore obtaining 
ATF3-deficient and potentially yet resistant clones. ShRNA knockdown in resistant cells, 
however, did not induce a re-sensitization of the cells to therapy in terms of effect on 
proliferation, cell cycle and apoptosis. This indicates that ATF3 is an essential gene in the gene 
rewiring processes in the early phase of resistance to cope with the stress induced by the 
therapy, but once the cells have become fully resistant, ATF3 is not needed for the 
maintenance of the resistant phenotype. This is an important indication for the clinical aspect 
of endocrine therapy resistance treatments. The efficiency of combinatorial treatments is highly 
time-dependent, and the interference with specific pathways after resistance development 
might not be successful. In this way, ATF3 is a perfect example of a driver of the resistance 
process that should be tackled in early phases of treatment administration to obtain the 
desired effects. 
 
5.3. ATF3 regulates TGFB2 to induce MAPK pathway activation 
The overall rewiring of MAPK and AKT pathways in ATF3 knockdown and overexpression 
indicated that ATF3 likely does not directly regulate each individual proteins in the pathways 
but might act through the upregulation of an upstream mediator. The screening of ATF3 targets 
suggested TGFB2 as a possible candidate. TGFβ isoforms are known inducers of MAPK and AKT, 
especially in pathological conditions (Chapnick et al. 2011; Zhang 2009; Hamidi et al. 2017). 
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Additionally the crosstalk between TGFβ and ATF3 has been extensively documented in 
literature. TGFβ1 has been shown to induce ATF3, that in turn enhances TGFβ signaling and 
promotes cancer initiating feature in normal breast cell lines (Yin et al. 2010). Moreover TGFβ1 
was proven to induce ATF3 expression and its interaction with AP-1 proteins in TNBC cell lines 
(Gokulnath et al. 2017; Kwok et al. 2009). Additionally, TGFβ1 was reported to induce ATF3 in a 
promoter-specific manner, inducing only transcripts derived by the P2 promoter (Figure 46 a) 
(Miyazaki et al. 2009; Kha et al. 2019). While all these reports focus on TGFβ1, TGFβ2 has a 
similar structure and acts on the same receptor, transducing the signal through the same 
pathways (Hachim et al. 2018). Additionally, binding of ATF3 and AP-1 both in the promoter and 
enhancers of the TGFβ2 gene has been experimentally proven, suggesting a potential 
regulation through these transcription factors (Figure 46 b).  
Indeed RPPA profiling revealed that TGFβ2 stimulation was able to induce MAPK and AKT 
pathway activation both in MCF7 and T47D (sensitive and resistant), therefore having a similar 
role to TGFβ1. Additionally TGFβ2 stimulation induced the expression of ATF3 after 1 week, 
while no effect was detected in T47D. In RNAi experiments, however, TGFB2 knockdown did 
not influence the levels of ATF3. TGFβ2 is therefore able to induce ATF3 expression, but it is not 
essential for the maintenance of ATF3 expression. 
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Figure 46: ATF3 and TGFB2 gene layouts 
(a) Graphical representation of ATF3 promoters (A-I, A-II). Both the isoforms derived from the two 
distinct promoters code for the same protein  (modified from Kha et al. 2019). (b) USCS genome 
browser snapshot of TGFB2 gene with ATF3, JUN and FOS binding sites. 
 
On the other hand, ATF3 knockdown reduced TGFB2 expression in MCF7, while it surprisingly 
increased it in T47D. This opposite effect on the two cell lines remarks the context-dependency 
of ATF3. One major difference between MCF7 and T47D is the p53 status, with MCF7 having the 
WT protein while T47D carrying a mutated version (L194F) (Polotskaia et al. 2015). ATF3 is a 
known binging partner of p53, and it has been shown to co-localize with it in specific genomic 
sites and increasing its stability (C. Yan and Boyd 2006; J. Zhao et al. 2016). ATF3 is also able to 
bind mutated p53 in cells carrying hot-spot mutations conferring oncogenic activity, 
suppressing its oncogenic function. (Wei et al. 2014). However, no data is available on the 
specific binding of ATF3 to L194F mutated p53. The binding of ATF3 to WT and mutated p53 
could therefore affect several downstream targets of these transcription factors in different 
ways in the 2 cell lines.  
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5.4. ATF3 knockout impairs in vivo tumor growth under 
endocrine therapy 
Following the promising in vitro data on the role of ATF3 in proliferation, cell cycle, apoptosis 
rate and invasion, the knockout clones were tested in vivo in a xenograft mouse model. ATF3 
knockouts displayed slower growth in vivo under both TAM and LET treatment, confirming the 
in vitro results. Differently from their behavior in vitro, the knockouts also showed a slower 
growth without any treatment administration, indicating a possible role of ATF3 in controlling 
the baseline proliferation rate of the cells. One unexpected result was the lack of growth 
inhibition of WT cells in the LET treated group. This could be explained by the adverse effects 
LET has on pre-menopausal women: the reduction in the peripheral E2 levels activates the 
hypothalamic-pituitary axis; this increases gonadotropin secretion, which stimulates the 
ovaries, resulting in even increased E2 production (Scharl and Salterberg 2016). Therefore LET 
might have stimulated E2 production to levels sufficient to sustain the growth of MCF7 WT. The 
E2 levels, however, might still not be high enough to support the growth of the ATF3 knockout 
clones that show a delayed tumor growth. 
 
5.5. Patients data validate ATF3 role in the early response to 
endocrine therapy  
Cell lines are often considered artificial and non-representative of the complexity of tumors. To 
validate the clinical relevance of ATF3 and to exclude the possibility that my data could be cell 
culture artifact, several publicly available dataset were analyzed. Indeed ATF3 was induced 
upon treatment administration in patients' biopsies in all dataset analyzed. Strikingly, in one of 
them, ATF3 was detected as the most significantly changing gene upon endocrine therapy 
treatment, strongly validating the results obtained in the cell line models. Other publicly 
available datasets with information on treatment and survival (TCGA and Metabric) were 
investigated to correlate ATF3 expression with disease-free survival and overall survival. No 
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difference was detected using the level of ATF3 in the primary tumors as a prognostic factor 
(data not shown). This is in agreement with the concept of ATF3 being induced upon 
stress/treatment: the levels in the untreated primary tumors are not relevant in evaluating the 
patients’ response to therapy and predicting treatment outcome. For this, datasets with 
biopsies after treatment administration, coupled with long-term follow-up are needed to fully 
investigate ATF3 association with resistance in vivo, but unfortunately no such data is available. 
 
5.6. Barcoding approach uncovers distinct mechanisms of 
clonal selection in endocrine resistance 
Therapy resistance could arise following different mechanisms. One option is the expansion of 
pre-existing resistant cell populations that get selected under treatment due to clear growth 
advantage (Shaw et al. 2016; Yu et al. 2014). Alternatively selection could be mediated by a 
stochastic adaptation and selection of specific clones induced by the treatment itself or that 
have a favorable state, for example, in the expression levels of relevant genes at the time of 
treatment (Shaffer et al. 2017; Sharma et al. 2010; Hata et al. 2016). 
To address this in the context of endocrine therapy resistance in breast cancer I used a cellular 
barcoding approach to track single clones during treatment (Bhang et al. 2015). Two luminal A 
cell lines, MCF7 and T47D, and two treatment, TAM and E2 deprivation, were used. This 
approach allowed the investigation of several questions: I) Role of clonality in endocrine 
therapy resistance; II) Identification of the mechanisms of clonal selection (pre-resistant clones’ 
selection or adaptation); III) Identification of treatment-specific mechanisms IV) Identification 
of cell lines specific mechanism. 
The two different cell line displayed striking differences both in terms of the number of 
barcodes enriched and the types of selection. In absence of selective pressure no robust 
selection was detected. However few barcodes displayed a consistent enrichment among 
replicates, particularly in T47D. It is not unexpected that even without the presence of external 
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stimuli a selection of clones with a proliferative advantage took place, as it has been describe in 
other contexts. A notable example in E. coli showed that, over the time of 60.000 generation 
kept in the same media without stimuli, different strains were enriched in the population due 
to their better fitness (Good et al. 2017). Upon treatment pressure however, diverse scenarios 
were identified. Under TAM treatment, MCF7 did not displayed a strong selection of specific 
clones, with more than 100 barcodes having similar enrichment within one replicate, while the 
individual barcodes were mostly not recurrent in the different replicates. In T47D, however, 
few specific barcodes were selected. These barcodes were common among all the samples, 
even having the same frequency in four of them. This is of particular interest because, since 
they were detected in all the clones independently, it represents a selection of pre-resistant 
clones and not a random adaptation. 
One point to consider is that the relative frequency of the two enriched barcodes was strikingly 
similar in all the replicates. This is unexpected as physiological fluctuation should have resulted 
in distinct frequencies in the independent replicates. A possible explanation of this observation 
is that two barcodes had integrated into the same initial cell that therefore has been labeled 
with two barcodes instead of one. However, independently from being one or two separate 
clones, a clear selection of resistant clone/s took place. The high frequency of these two 
barcodes, that potentially hints to just one clone having been selected in four replicates, might 
also be related to the genomic integration site. Viral integration might have disrupted the 
genetic locus as a result of integration of the viral sequences thus positively regulating nearby 
genes providing a selective advantage to the clone. The non-occurrence of these barcodes in E2 
treated or LTED cells hints that this had not provided the cells with a general growth advantage, 
but that this would be directly associate with growth in presence of TAM. To rule out a possible 
lucus disruption effect, analysis of the integration sites was performed. The viral integration 
analysis indicated that the two barcodes inserted in genomic regions not annotated as coding 
regions or regulatory elements, therefore not directly affecting the expression of any gene in 
their proximity. Additionally, the frequency of the two integration sites was not similar, 
indicating that the barcodes represent two distinct cell clones.   
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In LTED treatment, the mechanisms of resistance development were apparently more similar in 
the two cell lines. Indeed, a selection of one to six clones gave rise to the resistant population in 
both of the cell lines. Surprisingly enough, apart from one barcode enriched also in the WT that 
therefore can be considered not only resistance-related, all the resistant replicates presented 
different enriched barcodes, indicating a stochastic selection in each of the single replicates. 
A barcoding approached has recently been applied also by the Polyak group where MCF7 were 
treated with TAM and fulvestrant (FULV). With >90% of all barcodes shared among four MCF7 
TAMR replicates and >70% shared between the two different treatments (Hinohara et al. 2018), 
their data is in high contrast with that described in this thesis. Indeed, I did not see more than 
10% barcodes overlap between four or five replicates in MCF7 TAMR and really few barcodes 
were shared among treatments (and not consistently in the different replicates). Therefore 
their conclusion that resistance in MCF7 is mediated by selection of pre-resistant, genetically 
distinct cells does not fit with the results described above. Additionally, there might be doubts 
about their claims, as the genetic analysis they use as proof is performed on a different set of 
cells, not fitting to the overall design of the study. However, such selection might still have 
occurred in T47D TAMR, but a deeper characterization of the resistant clones and the initial 
population is needed to define if a genetically or epigenetically driven selection had taken 
place. 
Mechanisms of stochastic adaptation that appear to be the clonal selection method in both 
LTED treated cell lines has been described in other contexts. For examples, Gefitinib treatment 
in lung cancer revealed the existence of a subpopulation of cells in a reversible resistant state 
that was selected due to their stochastic phenotype at the moment of drug treatment (Sharma 
et al. 2010). A similar selection mechanism has been reported in vemurafenib treatment of 
melanoma, where transient pre-resistant cells were selected by the drug because they were 
stochastically expressing defined gene sets at the start of the treatment (Shaffer et al. 2017). 
These cells are then described to stabilize this transient state to a stable resistant phenotype, 
eventually with additional genetic or epigenetic alterations. This could explain the selection of 
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distinct barcodes in the long term estrogen deprived replicates, as different cells might have 
been in a transient resistant state at the beginning of the treatment and being selected. 
 
5.7. Resistant replicates have different pathway alterations 
and putative druggabilities 
The differences in clonal composition opened the question of phenotypic similarities among the 
independent resistant replicates. To investigate this, RPPA was used to assess their activation 
profiles for pathways involved in resistance. It has to be noted that the RPPA approach used 
here considers the pooled replicates, where specific pathways’ alterations of individual 
subclonal populations might be masked. Replicates with peculiar clonal composition had drastic 
differences in profiles compared to other replicates that comprised a larger number of 
individual clones. For example, replicates MCF7 LTED_5 and T47D LTED_2 had one predominant 
barcode each, indicative of clonal selection. In MCF7 LTED, replicate 5 showed high activation of 
all pathways screened, while other clones had more pathway specific activation profiles, like 
replicates 1 and 4 for the WNT pathway and replicate 1 for PLCγ. In T47D LTED the distinct 
profile of replicate 2 is even more obvious, as all the other replicates displayed highly similar 
pathway activation profiles. For MCF7 TAMR cells the profiles were almost identical, despite 
having completely different enriched barcodes. This hints to the fact that the mechanism of 
resistance development in this cells is acquired, and that the resistance is not acting through 
selection but rather a convergent adaptation of surviving cells.  
Interestingly T47D TAMR replicates, characterized by the same barcode composition, were also 
similar in terms of pathways activation, but presented replicate-specific features as well. Clear 
examples are replicate 1, that displayed high AKT/mTOR pathway activation, and replicate 2 
that showed a rather active MAPK pathway, with high levels of phosphorylated MEK and ERK. 
These findings indicate that, even though deriving from the same initial cells, these replicates 
acquired new molecular features during the resistance process that made them different from 
one another. This mechanism of diverse alterations arising during treatment from the same 
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persister cell has been described in other cancer entities and can be applied to endocrine 
therapy as well (Ramirez et al. 2016). This alterations can be either stochastic or drug-induced 
in a replicate-specific manner thereby conferring different final resistant profiles (Shaffer et al. 
2017). Also in tamoxifen resistance, a previous study had shown differential sensitivity of 
specific resistant clones to a panel of cytotoxic drugs, therefore demonstrating different paths 
to resistance (Kangaspeska et al. 2016).  
The fact that resistance to endocrine therapy is not only cell line and treatment specific, but 
also individual replicates arising from the same starting pool could have developed different 
resistance mechanisms, makes this a really challenging phenomenon to study. In addition the 
ever-changing features of cancer cells in culture make it even harder to establish unique 
mechanisms in cancer research. MCF7 themselves, when compared across 27 strains obtained 
from different labs, showed drastic differences both at the genomic and transcriptomic levels, 
as well as in drug sensitivity (Ben-David et al. 2018). It is therefore not surprising to see 
differences between the mechanisms of tamoxifen in MCF7 described in this thesis and the 
ones described by Polyak and colleagues, as even the cell line of origin in the two labs might 
have had distinct features (Hinohara et al. 2018). 
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6. Conclusions and Outlook 
In this thesis I addressed the issue of resistance development in breast cancer with two 
approaches aimed to investigate novel mediators of resistance and identify mechanism 
underlying clonal selection under treatment. 
In the first part of this study I analyzed the early events in resistance development and found 
ATF3 as a putative driver of this phenomenon through a rewiring of MAPK pathway. Indeed the 
interference with ATF3 expression caused an increase in drug sensitivity, while its 
overexpression induced a more resistant-like phenotype in sensitive cells. This was supported 
by changes in the MAPK pathway and in downstream effectors. Interference with ATF3 in 
resistance cells did not result in increased sensitivity, proving the role of this gene in the 
regulation of resistance acquisition process rather than the maintenance of the final resistant 
state. The role of ATF3 was also confirmed in an in vivo xenograft model and its upregulation 
was detected also in patient datasets, therefore demonstrating clinical relevance of the 
findings. 
While the role of ATF3 was established through these results, the mechanism by which it 
mediates resistance needs to be further investigated. Particularly it needs to be clarified if its 
rewiring of the MAPK pathway is direct or mediated by any of its target genes (e.g., TGFB2, JUN, 
FOS). Additionally, as ATF3 trascripional activity is also mediated by its binding to other co-
factor, it needs to be tested if particular binding partners are preferred in the resistance 
process. Several experiments are on-going to elucidate these points: 
 IP-MS (Immunoprecipitation coupled to Mass Spectrometry) to identify specific binding 
parners of ATF3 at different stages of resistance development.   
 ChIP-qPCR of ATF3 at the regulatory elements (promoter and enhancers) of ATF3 target 
genese, to test if the regulation is mediated by ATF3 direct binding 
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Due to the observed differences between MCF7 and T47D and the impossibility to obtaining 
knockout cells for ATF3 in the latter cell line, more efforts are also needed to demonstrate if 
ATF3 might be relevant only for a subset of luminal A tumors.  
The second part of this thesis addressed the mechanisms underlying resistance development in 
terms of clonal selection. Using a barcoding approach I identified differential mechanism of 
clonal selection based on the cell line and treatment used. These different mechanisms and 
clonal enrichments are reflected on distinct pathway profiles and putative drug sensitivities.  
I am currently performing a screening with several inhibitors for specific proteins of the 
pathways tested in RPPA to investigate the differential sensitivity of single replicates to 
particular drugs. 
A series of next generation techniques might be used to investigate the causes of the different 
barcodes selection and to explore if these genetic/epigenetic features are present in the initial 
population or are drug induced. Deconvolution to single clones might allow analyzing and 
interfering with specific alterations in a pure population derived from a single initial cell and 
further identify specific resistance mechanisms and pathways sensitivities. 
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Abbreviations 
4E-BP1 Eukaryotic translation initiation factor 4E-binding protein 1 
ACTB  β-actin 
AI    Aromatase inhibitors 
AKT  Serine/Threonine Kinase 1 
ATF3  Activating transcription factor 3 
BAMBI BMP and activin membrane bound inhibitor 
BCA  Bicinchoninic acid protein assay 
BSA  Bovine serum albumin 
BL  Basal-like 
BrdU  Bromodeoxyuridine 
Cas9  CRISPR associated protein 9 
CDK  Cycling dependent kinase 
cDNA  Complementary deoxyribonucleic acid 
ChIP  Chromatin immunoprecipitation 
CO2  Carbon dioxide 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeat 
CSNK1A1 Casein kinase 1 alpha 1 
CSNK1E Casein kinase 1 epsilon  
CTNNBIP1 Beta-catenin-interacting protein 1 
CTRL  Control 
DCIS  Ductal carcinoma in situ 
DKK1  Dickkopf-related protein 1 
DNA  Deoxyribonucleic acid 
DMEM Dulbecco’s modified eagle’s medium 
DMSO Dimethyl sulfoxide 
E2  Estrogen 
EDTA  Ethylenediaminetetraacetic acid 
EGFR  Epidermal growth factor receptor  
ER  Estrogen Receptor 
ERα  Estrogen Receptor α 
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ERBB2 Erb-B2 Receptor Tyrosine Kinase 2 
ESR1  Estrogen receptor 1 
EtOH  Ethanol 
FACS  Fl 
FC   Fold change 
FITC  Fluorescein isothiocyanate 
FBS  Fetal bovine serum 
GRB2  Growth factor receptor-bound protein 2 
GSK-3α Glycogen synthase kinase 3 alpha 
GSK-3ß Glycogen synthase kinase 3 beta 
HDAC  Histone deacetylase 
IDC  Invasive ductal carcinoma 
IHC  Immunohistochemistry 
JNK  c-Jun N-terminal kinase 
KO  Knockout 
LRP5  Low-density lipoprotein receptor-related protein 5 
LTED  Long term estrogen deprivation 
MAPK Mitogen-Activated Protein Kinase 
MOI  Multiplicity of infection 
MPER  Mammalian Protein Extraction Reagent 
mRNA Messenger ribonucleic acid 
MSK  Mitogen and stress activated kinase 
mTOR Mammalian target of rapamycin kinase 
NaF  Sodium Fluoride 
NFκB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
PAM  Protospacer adjacent motif 
PBS  Phosphate buffered saline 
PDK1  Phosphoinositide-dependent kinase 1 
PFA  Paraformaldehyde 
PI  Propidium iodide 
PI3K  Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PI3KCA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha  
RNA  Ribonucleic acid 
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RPS6  Ribosomal protein S6 
OE  Overexpression 
ON  Overnight 
p  Phosphorylated 
P/S  Penicillin/Streptomycin 
PLC  Phospholipase C 
PR  Progesterone receptor 
PTEN  Phosphatase and Tensin Homolog 
PVDF  Polyvinylidene fluoride 
qRT-PCR Quantitative reverse transcriptase polymerase chain reaction 
Rb  Retinoblastoma-associated protein 
RIPA  Radioimmunoprecipitation  
RNA  Ribonucleic acid 
RNAi  Ribonucleic acid interference 
RPPA  Reverse phase protein array 
RT  Room temperature 
SEM  Standard error of the mean 
SD  Standard deviation 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM  Standard error of the mean 
SERD  Selective estrogen receptor degrader 
SERM  Selective estrogen receptor modulator 
siRNA  Small interfering ribonucleic  acid  
SOS  Son of sevenless 
TAM  Tamoxifen 
TAMR Tamoxifen resistant 
TBS-T  Tris buffered saline with 0.1% Tween 20 
TCGA  The cancer genome atlas 
TGFβ  Transforming growth factor β 
TNBC  Triple negative breast cancer 
TP53  Tumor protein 53 
TSS  Transcription start site 
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UCSC  University of California, Santa Cruz 
Wnt  Wingless-type MMTV integration site family 
WT  Wild type 
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